Western University

Scholarship@Western
Electronic Thesis and Dissertation Repository
8-2-2016 12:00 AM

Characterization and personalization of botulinum toxin type A
therapy for upper limb tremor in Parkinson disease and Essential
tremor patients using multi-sensor kinematic technology
Olivia Samotus, The University of Western Ontario
Supervisor: Dr. Mandar Jog, The University of Western Ontario
A thesis submitted in partial fulfillment of the requirements for the Master of Science degree in
Neuroscience
© Olivia Samotus 2016

Follow this and additional works at: https://ir.lib.uwo.ca/etd
Part of the Nervous System Diseases Commons, Neurosciences Commons, and the Other Analytical,
Diagnostic and Therapeutic Techniques and Equipment Commons

Recommended Citation
Samotus, Olivia, "Characterization and personalization of botulinum toxin type A therapy for upper limb
tremor in Parkinson disease and Essential tremor patients using multi-sensor kinematic technology"
(2016). Electronic Thesis and Dissertation Repository. 4035.
https://ir.lib.uwo.ca/etd/4035

This Dissertation/Thesis is brought to you for free and open access by Scholarship@Western. It has been accepted
for inclusion in Electronic Thesis and Dissertation Repository by an authorized administrator of
Scholarship@Western. For more information, please contact wlswadmin@uwo.ca.

Abstract
Tremor commonly affects the upper extremities in essential tremor (ET) and Parkinson disease
(PD) patients where many experience functional disability and ultimately seek therapy. As ET and
PD tremor features overlap and clinical assessment is challenging due to its highly complex
nature, misdiagnosis is common resulting in unsuitable therapies and prognosis. Current treatment
options for ET and PD tremor include pharmacotherapy, focal therapy with botulinum toxin type
A (BoNT-A) injections, and surgical interventions which provide modest relief of tremor.
However, such therapies are commonly associated with significant adverse events and lack longterm efficacy and tolerability. Hence lack of standardized, objective measures of tremor and
suboptimal treatment options are two significant unmet needs faced by neurologists today. The
hypothesis of this thesis was to determine whether joint tremor amplitude can differentiate
between ET and PD tremor types and can be applied towards improving BoNT-A tremor therapy.
The first objective was to apply motion sensor kinematic technology to investigate the role of
paired tasks in modulating tremor biomechanics in 24 ET and 28 PD participants. Paired tasks
involved variating limb positioning while at rest, posture, and under weight-bearing conditions.
Motion sensor devices were placed over the wrist, elbow and shoulder joints capturing joint
angular tremor amplitude in multiple degrees of freedom (DOF). Kinematic measures of tremor
allowed detailed segmentation of tremor into directional components, which cannot be performed
visually. The relationship of joint tremor severity between paired tasks and across all tasks
generated unique tremor profiles and provided a simple method to differentiate ET and PD tremor
types. The second objective was to apply tremor kinematics to better tailor BoNT-A injection
parameters. Participants were injected in the upper limb, which exhibited their most bothersome
tremor, every 16 weeks, a total of 3 injection cycles, and attended follow-up visits six weeks
following treatment, for a total of 6 study visits. Clinical rating scales and kinematic recordings
were conducted at each visit. Dosing was based on clinician’s experience and kinematic data, and
muscle site of injection was determined kinematically. A significant decrease in mean clinical
tremor rating scores during rest and action tasks and significant improvement in arm function was
observed at week 6 and continued throughout the study in both ET and PD individuals. Ten PD
participants and eight ET participants reported mild weakness in injected muscles that had no
interference with arm function. Kinematic technology is a promising method for standardizing
assessments and for personalizing BoNT-A therapy.
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Preface
Tremor is the most common movement disorder encountered by clinicians today and is one of
the most challenging symptoms to treat. Despite the high prevalence of tremor, limited
progress has been made in treating tremor due to the relatively unclear understanding of many
underlying conditions, such as PD and ET. The prevalence of ET markedly increases with age
approximately affecting 6.3% globally and 14.3% in Canada of those aged > 65 years old1 and
more than 70% of PD patients have tremor as the presenting feature. As there is no
standardized technique to distinguish among common tremor types, misdiagnosis rates in PD
and ET are as high as one-third and hence lies a great interest in developing simple, objective
techniques to distinguish such tremor types. All traditional pharmacological agents
recommended for tremor therapy in PD and ET patients are approved to treat other conditions
(e.g. anticonvulsants, beta-blockers) and thus produce suboptimal tremor relief coupled with
significant adverse effects. A focal therapy with BoNT-A injected into tremulous muscles has
shown past success in tremor relief although prominent muscle weakness has resulted in early
discontinuation of therapy. This thesis demonstrates that accurate and intelligent kinematic
measurement addresses the significant unmet need for more objective measures to differentiate
tremor types and facilitate advances in tremor therapy.
Chapter 1 is an account of what has been published regarding upper limb tremor in PD and
ET and current practices involved with tremor therapy. The aim of this thesis was to develop
wearable technology that was feasible to differentiate tremor profiles and to improve focal
therapy by individualization of BoNT-A injection parameters.
Chapter 2 is a report of the differentiation of ET and PD tremor types in the upper limb by
weight-loading and paired task variations using angle-based kinematic technology.
Chapter 3 and 4 summarize the use of kinematic technology to measure tremor biomechanics
and to enhance efficacy and tolerability of BoNT-A for ET and PD tremor. Tremor kinematic
measures from each individual were utilized for muscle selection and calculating BoNT-A
dosages thereby ultimately personalizing therapy.
Chapter 5 states the key findings from Chapters 2, 3 and 4 and the concluding statements
regarding the impact in the advancement of tremor therapy and future directions.
xi

1. Introduction
1.1. Parkinson’s disease: the importance of tremor and its pathogenesis
More than 10 million people worldwide suffer from a major neurodegenerative disease
including Alzheimer’s disease, multiple sclerosis, and PD, which is expected to grow
significantly as the aging population lives longer and grows over the next few decades.
Affecting 1% of the population older than 60 years, PD is a chronic, neurodegenerative
disease with a broad spectrum of motor and non-motor features.2 The prevalence of PD
increases with age and is projected to continue to rise in parallel with our aging population.
While the neuropathology is generally well understood, the etiology remains a mystery.
A 60-80% loss of dopaminergic neurons within the substantia nigra pars compacta (SNc) of
the lateral ventral tier located in the basal ganglia (BG) and presence of Lewy bodies are
significant pathological findings in PD.2,3 A lack of dopamine producing neurons leads to
dopamine depletion in the striatum, particularly in the dorsolateral putamen. Genetic
mutations, mishandling of misfolded proteins ubiquitin–proteasome, the autophagy–
lysosomal systems, mitochondrial dysfunction and increased oxidative stress are identified as
contributing mechanisms underlying the death of dopaminergic and non-dopaminergic cells
in PD.4 Early in the disease, dopamine deficiency is the predominant neurochemical
abnormality and is thought to be strongly linked to bradykinesia and rigidity, unlike the
generation of tremor which remains unclear. As the disease progresses, involvement of nondopaminergic brain regions results in levodopa (dopamine)-resistant motor and non-motor
symptoms.2 Even though the first descriptive account of PD was written in 1817 by James
Parkinson, there is still an uncertain understanding of the mechanisms behind the occurrence
of dopaminergic deficiencies in PD.5 A better understanding of underlying mechanisms could
help offer new possibilities for symptomatic treatments aimed to improve function and
quality of life in PD patients.

PD presents in a sporadic, idiopathic fashion.6 It is marked by primary motor symptoms of
bradykinesia (slow voluntary movement), muscle rigidity and tremor often with postural
instability and gait disturbance (PIGD) occurring later in the disease course. Non-motor
1

symptoms experienced by PD patients may include mood disorders, cognitive disorders and
sleep disorders. The progression of PD and the manifestation of motor and non-motor
symptoms vary considerably from patient to patient although 69% of patients reveal tremor
at disease onset and 75% of patients will develop tremor during the course of their disease.7,8
Tremor is clinically and pathologically distinctive from the other parkinsonian features.
Tremor expression and severity may be associated with a genetic background and can also be
associated with disease course and prognosis.8 PD patients with a tremor-dominance show
evidence of a milder disease course and a better prognosis in terms of life expectancy
compared to patients with predominant PIGD symptom profiles.8,9 The PIGD subtype has a
larger annual increase in symptom severity, faster progression to Hoehn and Yahr grade 4,
worse cognitive performance, and a higher degree of disability at 5 and 8 years of disease,
compared to the tremor-dominant subtype.7 Despite these differences, both PD subtypes have
a similar disease duration at the time of death and thus tremor is not predictive of longer
survival rates.9 It is unclear whether resting, postural/action tremor or a combination of the
two tremors best describes this tremor-dominant subtype.

Tremor pathogenesis in both PD and ET are linked with elevated activity within the
cerebello-thalamo-cortical circuit. However, in PD, it is thought that dopaminergic
dysfunction of the pallidum, particularly originating from the loss of dopaminergic
projections from the retrorubral area, generates this increased activity.7,9 Tremor severity is
not related to the amount of dopamine deficiency in the SNc determined pathologically.10
Anatomically, the BG and cerebellar circuits are connected. The cerebellar nuclei project
glutamatergic, excitatory projections to the posterior part of the ventrolateral thalamus
whereas the globus pallidus interna (GPi) within the BG projects GABAergic, inhibitory
projections to the anterior part of the ventrolateral thalamus. Hence, motor cortical activity is
facilitated by activity of the cerebellar outputs and inhibited by GPi outputs. In addition, the
cerebellar nuclei have GABAergic, inhibitory projections to the inferior olive which sends
excitatory projections to Purkinje cells in the cerebellar cortex and cerebellar nuclei.7 BG and
thalamus activity are synchronous with tremor, though the region in which this occurs varies.
High synchronous activity with tremor has been found in posterior ventrolateral thalamus
2

neurons.11 These findings propose that the driving force of rest tremor is not within the BG
but is from the posterior ventrolateral thalamus.12 A metabolic imaging study using positron
emission tomography (PET) outlined the sensorimotor cortex, rostral cerebellum, dentate
nucleus, and putamen regions synchronous with tremor, which correlated with clinical tremor
scores, in those with the tremor-dominant subtype.13 In 2011, Mure and colleagues reported
that posterior ventrolateral stimulation reduced tremor amplitude and reduced the metabolic
activity in both the cortico-cerebellar circuit and within the BG suggesting a relationship to
tremor severity and a convergence in the motor cortex.13 Currently, there are three
hypotheses regarding the cause of PD resting tremor: the thalamic pacemaker hypothesis, the
basal ganglia pacemaker hypothesis, and the dimmer-switch hypothesis.7,9

The basis of the thalamic pacemaker hypothesis originates from studies observing the
intrinsic biophysical properties of guinea pig thalamic neurons which are single cell
oscillators at distinct frequencies, 9-10 Hz and 4-6 Hz, when neurons are slightly depolarized
producing low-threshold calcium spikes (LTS) or hyperpolarized, respectively.7 These
frequency ranges within the ventrolateral thalamus are similar to the frequency of PD tremor
and the presence of LTS in the thalamus was also identified in PD patients. However, the
presence of LTS may not be tremor-related as LTS was observed in both PD subtypes and
tremor-dominant patients exhibited “tremor-locked bursts” without LTS. In contrast,
“tremor-locked bursts” may be formed by LTS in the thalamocortical circuit.14 It is thought
that LTS may be generated by the increased inhibitory activity from the GPi to the thalamus
which would suggest tremor production occurs in the anterior ventrolateral thalamus.14 This
hypothesis contrasts the effect of tremor suppression by targeting the posterior ventrolateral
thalamus with deep brain stimulation (DBS). As there may be other brain regions that
hyperpolarize thalamic neurons, this hypothesis does not explain why stimulating the BG
reduces tremor. The advantage of this model is that it illustrates the fundamental role of the
posterior ventrolateral thalamus.

3

The BG pacemaker hypothesis identifies the BG as the area of excessive synchronization
which results in tremor. This hypothesis proposes that striatal inhibition of globus pallidus
externa (GPe) neurons and the excitatory subthalamic nucleus (STN) generate the pacemaker
by forming a feedback system that engages in synchronized bursting.7,15 Previously described
with in vitro data, the frequency of BG oscillations is between 0.4 and 1.8 Hz, which is lower
than the associated frequency ranges of PD tremor.7 A computational model demonstrated
that STN and GPe are prone to LTS bursts due to the increased feedback of the dopamine
depleted BG circuitry. This model definably explains the role of dopamine depletion within
the BG but fails to elucidate the causal role of tremorgenesis by the cerebellothalamocortical
circuit.

The dimmer-switch hypothesis is based on imaging studies in tremor-dominant and nontremor PD patients and suggests that the BG triggers tremor episodes and the
cerebellothalamocortical circuit modulates tremor amplitude. Data indicates that dopamine
depletion in the pallidum correlates with tremor severity and that the tremor-dominant
subtype has increased functional connectivity between the BG and the
cerebellothalamocortical circuit. This model explains why DBS in the BG (GPi or STN) or in
the ventrolateral thalamus can suppress tremor. 7

1.1.1. Classification of PD tremor
Tremor is an involuntary, rhythmic movement affecting one or more body parts but most
commonly affects the upper limbs and hands. Tremor varies depending on the circumstances
under which they occur. PD patients with tremor can demonstrate different types of tremor:
at rest, with posture, action/kinetic or orthostatic. Typical PD tremor is observed unilaterally
or asymmetrically in the upper limb at rest, while the body part is completely supported by
gravity, with a frequency between 4 and 6 Hz. However, in more advanced disease, tremor
may appear bilaterally in the upper limbs. Approximately 34-60% of PD patients may also
present with a tremor produced by a voluntary contraction called a postural tremor, when
arms are outstretched in front of the chest.16 Kinetic tremor occurs during any voluntary
4

movement including non-target directed and intention tremor where the amplitude increases
towards the target. Postural and action tremors are typically delayed compared to ET, and is
described as a re-emergent tremor (with a mean delay of ±10 seconds);16 tremor frequency is
higher than 1.5 Hz and is within a similar frequency range as a resting tremor.16 As the
frequency of resting and re-emergent tremors is similar, this suggests that both tremors
originate from similar pathophysiological processes. Aside from tremor in the arms, patients
may exhibit rest tremor in the lips, jaw or in the lower extremities.

Isolated postural and action tremors can occur in PD with a frequency varying between 4 and
9 Hz.9 Postural tremor without parkinsonian features is often diagnosed as ET and is
observed more frequently in those patients with a family history of PD.16 Some PD patients
have postural tremor similar to ET for many years before the onset of PD features suggesting
that ET is a potential risk factor for PD.4 Orthostatic tremor, a position-dependent postural
tremor, can be isolated or co-exist with resting tremor with different frequency ranges (4-6,
8-9 or 13-18 Hz) and responds to dopaminergic treatment suggesting that it is a manifestation
of PD rather than an association of ET and PD tremor types.9 In some cases, postural and
kinetic tremors can be more disabling than rest tremor and may present as an initial symptom
prior to diagnosis.4

Tremor is a unique symptom of PD in that the rate of tremor progression and severity is
unlike the other PD symptoms such as bradykinesia, rigidity, balance and gait. Tremor is
complex to visually assess and the manifestations of tremor can challenge proper diagnosis
and ultimate prognosis triggering high misdiagnosis rates when using the current
classification system by the Movement Disorders Society (MDS).17

1.1.2. Current treatments of PD tremor
Investigations into understanding the pathogenesis of PD and providing new insights into the
mechanism of cell death, connectivity of the BG, epidemiology, genetics, pharmacology and
5

neurosurgery has driven the focus of scientific advancement. While some of these advances
are translating novel therapeutics into clinical practice, true pathogenesis targeted treatments
are still lacking. This may be in part due to the need for better animal models that can better
mimic the progression of the disease. There is a lack of success for neuroprotective strategies
due to the scarce understanding of the various genetic, environmental, and other mechanisms
contributing to neurodegeneration in PD. Efficacy of therapeutics is tested using evidencebased medicine designed to control for placebo effects. However, there are limitations to
placebo-controlled randomized trials due to the inhomogeneous population of included
patients, the short-term nature of these studies and specified patient demographics, which is
not representative of clinical practice. This leads many physicians to rely on their own
experience and best clinical judgement in selecting the optimal treatment option and for the
therapeutic plans with patients.

Various treatment options are available to alleviate symptoms associated with PD. First line
therapy is the use of oral pharmacological agents while surgical intervention is generally
reserved for drug refractory PD. Generally, initiation of therapy is often delayed until
symptoms are functionally disabling and interfere with activities of daily living (ADLs) or
the patient’s vocation.18 Choice in therapeutics heavily depends on the patient’s age,
dominant symptoms, disease stage and cognitive state. Treatments are titrated and adjusted to
changes in patient symptomatologies. Approximately 10% of patients are selected for
surgical therapies.6

1.1.2.1.

Pharmacotherapy agents

Pharmacological treatments seek to correct the imbalance within the BG due to the loss of
dopamine producing neurons. There are many classes of dopamine replacement medications
that ultimately seek to alleviate motor impairments in PD.

6

If motor symptoms are mild and require therapy, dopamine agonists (pramipexole and
ropinirole), levodopa, or a monoamine oxidase type B inhibitor (MAOBI; selegiline or
rasagiline) can be administered to produce symptomatic benefit.2 Past studies show the use of
beta-blockers, often propranolol, may improve PD tremor and motor function;
anticholinergic medications are more effective than placebo for improving motor function
but are inconclusive as a tremor therapy and frequent adverse events, such as cognitive
impairments, dizziness, fatigue, tachycardia, lead to discontinuation.2 Clozapine has been
shown to improve bothersome or disabling PD tremor when used for tremor resistant to other
therapies though significant adverse events such as agranulocytosis, myocarditis, seizures
and sedation can occur.19 Six, small class 3 randomized-control trials have shown mixed
evidence for the possible efficacy of amantadine as a monotherapy or as an adjunct therapy
due to the poor quality of studies.2

Levodopa or dopamine agonists are prescribed for patients with more severe symptoms and
impairment in ADLs. Levodopa remains the gold standard in providing the greatest
symptomatic benefit for PD and is linked to lower incidences of freezing, hallucinations,
somnolence, impulse control disorders, and edema than initial treatment with dopamine
agonists. However, dopamine agonists greatly benefit patients younger than 60 years of age
or with younger-onset of disease and are associated with fewer dopaminergic motor
complications associated with levodopa, such as dyskinesia which can be more disabling
than the PD symptoms.2,20 A meta-analysis showed the long-term benefits of levodopasparing versus levodopa as an initial treatment and concluded that levodopa alone was more
effective in reducing Unified Parkinson’s Disease Rating Scale (UPDRS) parts I-III scores
though levodopa alone group were at a higher risk of developing dyskinesia and wearing-off
phenomenon.21 Interestingly, a study demonstrated that more than triple of patients receiving
levodopa-sparing therapy discontinued prematurely due to adverse events compared to
patients receiving levodopa alone therapy.21 New evidence shows that the early advantage of
dopamine agonists over levodopa diminishes over time (estimated 10 years).19 Those with
tremor as the initial manifestation of PD or having a tremor-dominant subtype have a lower
probability of developing levodopa-induced dyskinesia.22 Older, tremor-dominant PD
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patients would benefit from starting with levodopa compared with dopamine agonists. Thus,
levodopa and dopamine agonists appear to be reasonable options for initiating dopaminergic
replacement therapy but are associated with different efficacy and adverse effects.20

Unfortunately, levodopa and dopamine-replacement therapies do not target tremor and tend
to produce suboptimal tremor relief, and in some cases may worsen tremor. Additionally, it is
often tremor that is sub-optimally alleviated or is a persistent tremor despite improvement in
other cardinal PD symptoms, such as bradykinesia and rigidity, which are optimally managed
by levodopa therapy. Recent studies have reported that tremor is high up among the key
symptoms found to be one of the most bothersome symptoms experienced by patients.23,24
Many clinicians are inclined to simply increase medication dosages or introduce adjunctive
therapies. Dopamine agonists and anticholinergic medications can be used concomitantly
with levodopa to treat tremor but may be accompanied by neuropsychiatric and cognitive
side effects.18 In double-blind studies, levodopa combined with carbidopa known to increase
availability of levodopa in the brain, improves resting tremor by more than 50%, as well as
bradykinesia and rigidity compared to using levodopa alone.18 Efficacy of
levodopa/carbidopa formulations and dopamine agonists have been reported to reduce rest
and postural tremors to a similar level; however poor long-term efficacy and adverse events
arise.18 To reduce the incidence of adverse event profiles of oral, anti-tremor medications, a
focal therapy with BoNT-A has been suggested to be efficacious in providing tremor
reduction at the source, given the focal and asymmetric presentation of tremor.25

1.1.2.2.

Botulinum toxin type A focal tremor therapy

Treating upper limb tremor with BoNT-A has not been widely adopted in clinical practice.
However, BoNT-A is used to treat a wide variety of symptoms related to PD such as foot and
hand dystonias, blepharospasm, lid apraxia, sialorrhea, hyperhidrosis, and jaw tremor. When
injected intramuscularly, BoNT-A inhibits the release of acetylcholine (ACh) at the
neuromuscular junction resulting in the blockade of neuromuscular conduction and reduced
muscle activity/contraction. The release of ACh at the neuromuscular junction occurs by the
8

synaptic fusion complex of ACh vesicles bound to the pre-synaptic membrane by soluble Nethylmaleimide-sensitive factor attachment protein receptor (SNARE) proteins. SNARE
proteins mediate the docking and exocytosis of ACh vesicles at the presynaptic nerve
terminal. The proteolytic action of BoNT-A cleaves SNAP-25, one of the three proteins
which form SNARE, preventing the release of ACh into the synaptic cleft.26 BoNT-A at the
neuromuscular junction interrupts neurotransmitter release thereby causing muscle paralysis.
Thus, when BoNT-A is injected into muscles contributing to tremor, effective alleviation of
tremor can be achieved.27

There are limited number of studies reporting the efficacy of BoNT-A for PD tremor25
though the success of BoNT-A lies in individualizing therapy by accurately distinguishing
tremulous muscles.27 However most past studies treating ET, dystonic tremor, or PD tremor
used randomized or fixed dosing regimens based on visual/clinical assessments, which has
led to early discontinuation of therapy due to bothersome, dose-dependent muscle
weakness.28–30 The use of accelerometry and surface electromyography to identify arm
muscles with tremorogenic activity reduced incidence of weakness and improved functional
outcomes in ET.31 However, accelerometry provides an overall tremor severity score and is
not capable of providing a more detailed breakdown regarding which degree of freedom
(DOF) tremor is acting in.

1.1.2.3.

Surgical intervention

Stereotactic surgery is the next treatment option for patients with disabling tremor resistant to
pharmacotherapy. Tremor can be effectively reduced following DBS implantation or lesional
therapy.

1.1.2.3.1.

Deep brain stimulation

DBS is a surgical technique involving the implantation of electrodes in specific brain regions.
DBS has proven to be effective for controlling rest and postural tremor in PD.32 DBS is
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known to be more effective than oral medication in reducing rest tremor severity and
frequency.33 A recent study has shown that patients with early motor complications who
underwent DBS and medical therapy have significant improvements in ADLs and relief of
motor disability for two years compared to patients with medical therapy alone.34 DBS
significantly improved survival of severe, late-stage patients and reduced admittance to longterm care facilities compared to patients with no DBS.35

The electrodes are connected to a device called an implanted pulse generator (IPG) that
delivers electrical stimuli to brain regions in order to modulate or disrupt patterns of neuronal
activity associated to PD. Three specific sites in the brain are most commonly targeted for
DBS in PD: STN and GPi nuclei in the BG where much of the physiological modulation
occurs in PD, and in the ventro-intermediate thalamic nucleus (Vim).32 Bilateral DBS of the
STN (STN-DBS) is performed in patients who are levodopa responsive with persistent motor
symptoms despite optimal medical therapy. However, only a fraction of PD patients are
eligible for this neurosurgical intervention. Surgical selection criteria include patients
experiencing motor complications refractory to best medical treatment, who are levodoparesponsive, less than 65 years of age, with no mental health issues (depression, dementia) and
have had PD for more than 7 years. In addition, intracranial hemorrhage, infection, and postoperative seizures are the most common adverse events33 and impairments in gait, speech,
and balance have been shown to have less chance of improvement and in some cases may
worsen.6 When the DBS is turned on about 2-4 weeks following surgery, most patients may
require a reduction in medication dosages as the presence or severity of side effects such as
dyskinesias increase.

Electrical stimuli promote neurogenesis, increased blood flow to stimulated areas, and
astrocytes to release calcium and neurotransmitters including adenosine and glutamate.6
However, the exact mechanism of how DBS alleviates PD symptoms is not yet clear despite
these physical and physiological changes.32 High frequency STN-DBS suppresses the
excessive beta-frequency synchronization in PD patients, in a similar way to how levodopa
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reduces synchronous beta-frequency oscillations.36,37 However, the effect of how DBS
intervention improves appendicular symptoms such as tremor, rigidity, and bradykinesia
remains elusive.38
1.1.2.3.2.

Lesional therapy

A surgical procedure involving lesioning the GPi reduces motor fluctuations, tremor and
dyskinesias as the GPi is thought to be overactive in PD. This procedure, pallidotomy, is
performed unilaterally as bilateral procedures rarely occur due to high incidence of severe
adverse events including cognitive impairment, dysarthria, and dysphagia.6 The reduction in
PD symptoms by pallidotomy is not as great as DBS intervention.32 Suppression of tremor,
rigidity, dyskinesia and bradykinesia has been reported for five years following surgery
however bradykinesia gradually reoccurs with freezing of gait at a 10-year follow-up.6 In
addition, cognitive and executive functions are reduced after five and 10 year follow-ups and
thus, pallidotomy is an alternative to DBS or when DBS is no longer effective.6

An invasive procedure called thermal radiofrequency thalamotomy involves the passage of a
probe into the VIM nucleus of the thalamus, an area understood to be involved in the tremor
cerebello-rubro-thalamo-cortical circuit, and performing a lesion to the side contralateral to
the tremor. Bilateral thalamotomy may affect executive function by disrupting
neuroanatomical pathways between subcortical and prefrontal cortical areas. Unilateral
thalamotomy significantly improves PD symptoms of tremor, rigidity, mobility, well-being,
and ADLs.6 The use of transcranial magnetic resonance imaging (MRI)-guided high intensity
focused ultrasound to perform thalamotomy has reduced complications involving
hemorrhages, motor deficits and post-operative cognitive impairment.39 However, side
effects including paraesthesia of lips, tongue and fingers, nausea and pain at one year followup do arise.

Gamma knife is a non-invasive surgical approach involving the emission of highly focused
gamma radiation beams at a target within the brain pinpointed using imaging scans.6
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Improvements in tremor and ADLs have been demonstrated though benefits take several
months to appear. There are contrasting results on the effectiveness of gamma knife in
reducing rest, postural, action and head tremor. Gamma knife lacks the accuracy observed in
invasive procedures since there is no intraoperative electrophysiological confirmation of
target site.6 A large spectrum of possible complications involving the delayed effects of
radiation necrosis and thus such procedures are reserved for PD patients with severe
disabling symptoms who fail to adequately respond to pharmacotherapy.

1.2. Essential tremor: symptoms and etiology
ET is the most common adult-onset movement disorder after restless legs syndrome.1 The
prevalence of ET increases with age, affecting approximately 1% of the general population
and 2.3-14.3% of those aged 60 years and older.1 Approximately 70-80% of people with mild
ET do not seek therapy and go undiagnosed and thus, prevalence is underestimated. The
course of ET varies widely as in some patients the tremor remains mild while in others it
becomes progressively and functionally disabling that many seek effective treatment. The
slow, progressive nature of ET may evolve to more body parts/areas, increasing in amplitude
and frequency.40 The age of onset is a bimodal distribution with peaks at early childhood and
around the age of 60 years of age.41 A family history of ET and aging are risk factors for ET.
The etiology of ET is genetic by inheritance in a Mendelian autosomal dominant fashion in
approximately 50% of patients increasing the prevalence of ET within certain families 42
although, specific genes have not been identified.42 A positive family history is very common
and these ET patients have a younger age at onset.43 Non-genetic and environmental factors
are possible causes of ET yet are much less extensively studied.

ET is characterized by bilateral tremor during voluntary movement occurring most frequently
in the hands and arms in absence of other medications or neurological signs that might cause
tremor. Isolated head tremor with no signs of dystonia fall under ET. For definite certainty of
ET, ET must be present for over five years with thorough exclusion of other causes. ET is
now widely recognized as a condition associated with significant physical and psychosocial
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disability and over the past 20 years, investigators have sought to better classify and define
ET as growing literature considers ET to be a family of diseases.44 ET as a monosymptomatic
disorder has been challenged, as disturbances in gait, mood, cognition and hearing have been
observed and linked to thalamic and cerebellar dysfunction.44 Problems with postural
stability and gait are evident in patients with longer disease time. Nevertheless, ET is a
clinical syndrome of action tremor in the upper limbs (at least 95% of patients) and less
commonly in the head (at least 34%), face/jaw (7%), voice (at least 12%), tongue (30%),
trunk (5%), and lower limbs (30%).44
The pathophysiology of ET remains largely unknown as there is no known pathological or
biochemical findings, no suitable animal model and hence most knowledge about ET is
gathered from clinical studies. The frequency of ET ranges between 4 and 12 Hz and is
thought to emerge from neuronal oscillation in the cortico-bulbo-cerebello-thalamo-cortical
loop but the cause is unknown.44 Low frequency repetitive transcranial magnetic stimulation
(rTMS) over the posterior cerebellar cortex modulates the cerebello-thalamo-cortical circuit
resulting in significant reduction in tremor severity for three weeks.45 Oscillation in the
cortico-bulbo-cerebello-thalamo-cortical loop is also observed in PD, Wilson disease and
rhythmic cortical myoclonus. 40 The frequency of ET is associated with the dysfunction in
the central component as several central lesions in the pons, internal capsule, cerebellum and
frontal/sub-cortex modify ET. The peripheral component of ET modifies amplitude and is
linked to adrenergic mechanisms in the muscle spindle.46 A recent morphometric study
reported all ET cases present with histological change, 24% of ET showed Lewy body
inclusions and 76% had cerebellar pathology (Purkinje cell loss).47 Some studies report
altered gamma amino-butyric acid (GABA) function in ET.40

1.2.1. Classification of ET
Classical ET is bilateral, largely symmetrical, postural and/or kinetic tremor – although one
limb may be more pronounced than the other. Postural tremor is provoked when arms are
fully extended in front of the body though more pronounced tremor is observed when the
shoulder is abducted, elbow is flexed and hands are held under the chin.40 Kinetic tremor is
more pronounced when nearing the target and is called an intention or terminal tremor. This
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is tested by asking the patient to go back and forth between touching their nose and the
target. Completing Archimedes spiral and line drawings, pouring, and writing tasks are other
methods for testing action tremor.

Many ET patients are incorrectly diagnosed with PD.40 PD tremor during the early course of
PD may present as an action tremor without rest tremor, bradykinesia or rigidity thus making
it extremely difficult to distinguish early PD from ET. However, postural tremor in ET
manifests immediately on positioning arms horizontally where PD postural tremor has
delayed onset. Additionally, classical PD tremor is at rest however one-third of ET patients
have rest tremor which typically manifests later in the disease course.40 Rest tremor can be
elicited by physical or emotional stress and thus definite rest tremor should be evident when
the patient is lying down with the arms fully supported. Rest tremor is not a feature of
cerebellar disorders. Cerebellar tremor is slower than ET with variable amplitude, irregular
rhythm and is primarily a proximal, upper limb tremor, in contrast to the distal tremor of ET.
Dystonia with associated tremor is typically jerky and irregular occurring commonly in the
head and is most prominent when the body part is positioned in a direction opposite to the
direction of the dystonic side and thus may be considered a postural/kinetic tremor. A
sensory trick alleviates dystonia but does not improve ET. Physiological tremor occurs under
stressful situations and is non-progressive though frequency ranges from 8 to 12 Hz. Writing
tremor may be a feature of ET but is better associated with the dystonic posturing of the hand
classifying it as a dystonic tremor. Thus, proper positioning and tests are required in these
movement disorders as ataxic or dystonic features can be misinterpreted for tremor.

1.2.2. Current treatments of ET
As the basic neuropathology and neurotransmitter deficits in ET are largely unknown, no
disease-specific drug is available and all traditional oral agents used in treating ET were
primarily developed for other diseases.48 Treatment options currently available for ET
include oral pharmacotherapy, botulinum toxin A (BoNT-A) injection, and stereotactic
surgery, including DBS and thalamotomy.48–50 Various drugs, including propranolol, which
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is the only pharmacotherapy approved by the US Food and Drug Administration to date,
primidone, benzodiazepines, gabapentin, pregabalin, topiramate, and nimodipine are used in
the treatment of ET, with an average tremor reduction of 50% or less.48,50,51 Poor efficacy is
frequently coupled with dose limiting side-effects, such as drowsiness with primidone,
bradycardia, syncope, fatigue, and erectile dysfunction with propranolol. Additionally,
tolerance to the initial benefit often leads to the discontinuation of drugs in 56.3% of
patients.50 DBS of the VIM nucleus of the thalamus may benefit patients with disabling ET,
though only a fraction of patients are eligible for this highly invasive procedure that may
produce lasting neurological side-effects, including paresthesias (6-36%), dysarthria (318%), ataxia (6%), limb weakness (4-8%), balance disturbance (3-8%) and dystonia (29%).49,50 Efficacy and risks of gamma knife thalamotomy is comparable to VIM-DBS.49
Ultrasound guided thalamotomy can be performed only unilaterally and again carries the
same potential risks as gamma-knife surgery and thus large, randomized, controlled trials are
required to assess the procedure’s efficacy and safety.39,52,53 A review of the current,
recommended treatment options for ET is summarized in Table 1-1.

Table 1-1. Treatment options for ET.

Drug Name

Propranolol

Drug Class

Beta blocker

Level

A

Total
Daily
Dosage
(mg/d)

40 320

Sample
size

533

15

Efficacy
(compared to
baseline)

Adverse Effects

Nausea, vomiting,
bradycardia,
~50% of patients
diarrhoea,
respond. Those that
hypotension,
respond experience
drowsiness, fatigue,
a 50-60% reduction
light-headedness,
in tremor.
weakness and
paraesthesia

Reference

54,55

Primidone

Anticonvulsa
nt

Atenolol

Beta blocker

Alprazolam

Benzodiazepi
ne

Gabapentin
(monotherapy)

Anticonvulsa
nt

Sotalol

Betaadrenergic
receptor
antagonist

Topiramate

Anticonvulsa
nt

A

50 1000

B

50 150

B

0.125 3

B

B

B

1200 1800

75 240

25 300

218

50% mean
improvement rated
by clinical scales
and accelerometry

Ataxia, vertigo,
nausea, vomiting,
fatigue, malaise,
dizziness,
unsteadiness,
confusion,
impotence, rash

79

25% mean
improvement by
clinical scales, 37%
mean improvement
by accelerometry

Light-headedness,
nausea, cough, dry
mouth, sleepiness,
decreased pulse and
blood pressure

46

25-37% mean
improvement by
clinical scales

Mild sedative and
fatigue effects

61

Drowsiness,
fatigue, dizziness,
nervousness,
shortness of breath,
reduced libido

33% improvement by
clinical scales, 77%
improvement by
accelerometry

28% mean
improvement in
clinical scales

Serious ventricular
arrhythmias, doserelated QT interval
prolongation,
reduced alertness

29% improvement
in clinical scales
(mean dose=292
mg/d); 30%
improvement in
tremor (up to 400
mg/d) with a 32%
attrition rate due to
adverse events

Dizziness,
disorientation,
paraesthesia, weight
loss, memory
difficult, appetite
suppression,
cognitive difficulties,
upper respiratory
tract infection, taste
perversion, fatigue,
nausea, headache,
somnolence

50

335

16

51,54,55

51,54

51,54

51,54,55

51,52,54

51,55

Nimodipine

Clonazepam

BoNT-A

Calcium
channel
blockers

Benzodiazepi
ne

Neurotoxin

DBS

Unilateral or
bilateral
VIM-DBS;
STN-DBS

Thalamotomy

Gammaknife; MRIguided
Focused
Ultrasound

C

C

C

C

C

120

0.5 - 6

50 300
U/arma

16

44

283

398

181

17

45% improvement
by clinical scales
and 53%
improvement by
accelerometry
(n=14)

Headache, heartburn,
hypotension

45% improvement
by accelerometry

Drowsiness,
depression, cognitive
and behavioural
impairments

20-27%
improvement by
clinical scales
(n=133)

Dose-dependent
muscle weakness
occurred in 30% of
patients, reduced grip
strength, stiffness,
cramping, pain at
injection site

40-90%
improvement by
clinical scales up to
3 years. Chronic
stimulation
gradually worsens
efficacy leading to
loss of tremor
suppression in
about 70% of
patients

Dysarthria,
disequilibrium,
paresthesias,
weakness, headache,
intracranial
hemorrhage,
subdural
hemorrhage, lead
dislodgement,
generalized motor
seizures. About 18%
experience
equipment
malfunction or lead
displacement

55-90%
improvement by
clinical scales

Hemiparesis,
transient problems
with speech, motor
function, dysarthria,
verbal/cognitive
deficit, weakness,

51,54

51,54

51,54,56

54,56

51,53,54

(MRgFUS)

a

confusion, facial
paresis. About 7%
experience
permanent
complications
(hemorrhage and
infection).

BoNT-A units are in mouse units from mouse lethality assay

In addition to pharmacotherapy and surgical intervention for ET, BoNT-A injected into
tremulous muscles has demonstrated modest effect in reducing arm tremor in ET and
similarly for PD rest tremor. A randomized, double-blind study by Brin and colleagues
demonstrated in 133 ET patients a significant improvement in postural tremor up to 16 weeks
and kinetic tremor improvement for 6 weeks without any improvements in motor tasks and
functional disability.28 Common side effects such as hand muscle weakness restrict its
application as patients found the weakness more disabling than their tremor. The randomized
injection regimen is the probable cause of the resulting dose-dependent muscle weakness. In
fact, muscle weakness is often cited as the main and most severe adverse event of this
therapy reducing efficacy and ease of use in 45-60% of patients.29,30,57 Pacchetti and
colleagues identified tremulous wrist flexor/extensor and bicep muscles by more objective
measures such as accelerometry and surface EMG to better target BoNT-A; this resulted in
significant reduction in tremor amplitude and improved ADLs scores in 20 patients.31 Yet,
practice guidelines score a level C recommendation and believe BoNT-A has a modest effect
at best.48

1.3. Rationale
1.3.1. Using technology to differentiate ET and PD tremor types
There are no biochemical or radiological biomarkers in PD and ET and thus proper diagnosis
heavily relies on clinical observation. As ET and PD tremor have overlapping tremor features
and may occur in the same circumstances, reliable and accurate methods for differentiating
these tremor types are important. Possible biomarkers involving MRI, PET and SPECT
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scans, movements about the wrist, olfactory deficits, and REM sleep disorders have been
proposed for PD but none are satifactory.58 The criterion for ET is based on clinical
assessment of tremor however patients usually present with more than one type of tremor and
it is not clear whether ET is separable from different types of tremor.59 A study failed to
differentiate ET and PD tremor by combining EMG and kinematic analysis.58 As both
diseases are incurable and therapy is focused on alleviating symptoms and improving quality
of life, there is a great interest in differentiating between these diseases for proper
symptomatic management and reducing the economic burden to healthcare utilization,
caregiver costs and lost productivity.60

To quantify tremor in the clinical setting, standardized clinical rating scales such as the FahnTolosa-Marin (FTM) tremor rating scale, the Washington Heights-Inwood Genetic Study of
ET rating scale, Whiget tremor rating scale and UPDRS part III for the tremor motor
symptoms can be used in ET and PD.61 The FTM uses a 5-point scale rating tremor severity
based on tremor amplitude from 0 (no tremor) to 4 (severe tremor) in each part of the body.62
UPDRS ratings use an integer scale (0-4) to assess severity of motor functions rather than a
quantitative, ratio-based approach.63 UPDRS maintains high subjectivity as intra-individual
ratings vary, limiting its accuracy and value as a measure for clinical diagnosis and in clinical
trials/studies.64 In addition, questions and phrases used in scales are ambiguous, the
sensitivity of scores to change in clinical trials, and the differences in ratings between
patients and assessors needs to be revised.61,65 Tremor rating scales also lack good inter-rater
reliability and continuous/repetitive monitoring capabilities remain a concern. Thus there is a
need for more objective outcomes that can be applicable to clinical practice.66

Several targeted and sensor-based methods for monitoring and for analysis of tremor have
been developed over the past decades. Advantages in these emerging techniques include high
accuracy, repetitiveness and reliability of measurements and that the devices are small, noninvasive and are easy to use.67 The use of surface or needle-EMG involves electrical contacts
fixed on the skin or using a needle placed in a muscle to analyze duration of EMG activity
bursts. Patterns of muscle co-contractions can be observed and recent work has proven EMG
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recordings can classify ET apart from parkinsonian tremor.67 However, EMG analysis takes a
skillset and may not be practical in clinical practice. Gyroscopes and accelerometers are low
in cost, small, and are convenient to measure useful parameters such as frequency and
amplitude of tremulous body segments. Unfortunately, such tools have really only been
applied for clinical management and have not been successful in distinguishing pathological
tremor types. Flexible angular sensors called goniometers measure joint angles and are
frequently used in sports and rehabilitation 67 Currently, goniometers have not yet been
applied in large scale studies of tremor and thus it is unknown whether these sensors can
detect differences between tremor characteristics in PD and ET patients.67 However, recent
studies have demonstrated that kinematic technology for tremor characterization is a reliable
and feasible methodology and have generated the ability to distinguish tremulous muscle
groups.68–71

Owing to the lack of standardized methodologies to measure upper limb tremor, this current
thesis focused on the use of wearable, motion sensor technology to quantify the tremor
biomechanics at each arm joint in PD and ET individuals while individuals were in their best
medically managed state. By deconstructing joint tremor amplitudes in each individual over
a series of tasks, differences in tremor profiles were established thereby enabling an
objective, simple method to distinguish between ET and PD tremor types.

1.3.2. Using technology to personalize therapy
Many tremor analysis tools are very expensive and are generally non-portable, such as an
optical motion capture system.67 Multi-sensor motion recordings, wearable
accelerometers/gyrostats, and tremor apps for smartphones (based on accelerometry) to
measure tremor have been established and are available for the general public. Such
technological advances allow in-home monitoring, individualized therapy titrations, and is a
diagnostic insight for clinicians.72 However, wearable devices are not reliable measures in
distinguishing tremulous muscles and do not provide accurate or diagnostically relevant
information about tremor. Therefore, those who use these apps and wearable devices for
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patient care or as outcome measures in clinical studies should exercise caution as there are a
limited number of studies investigating the validity of these devices for tremor analysis.

Current research focuses on the use of portable and simple to use devices that provide
applicable information for clinicians to better individualize therapy. One study extracted
tremor characteristics, such as frequency, direction and amplitude, from spiral drawing on a
digitizing tablet. Writing and spiral drawing tasks have recently been used as an objective
measure of proximal versus distal arm tremor severity.73 However tremor characteristics
during rest or other functional tasks could not be measured.72

While BoNT-A injection in the upper extremities is a viable treatment option as a
monotherapy or adjunctive therapy for ET and PD tremor, limited functional efficacy due to
dose-dependent wrist and finger muscle weakness remain a concern. The use of injection
protocols involving fixed BoNT-A dosages and predetermined muscle sites, regardless of
patient’s unique tremor characteristics are probable reasons for this problem.74,28 During a
tremor assessment, the characterization of the movement dynamics along the whole arm,
muscle selection, dosing and proper muscle localization during injection are important
considerations when utilizing BoNT-A to enhance arm function and to minimize likelihood
of weakness.27,68,69 While clinical knowledge and use of technologies, such as EMG or
ultrasound aid in muscle localization and injection, visually-guided assessments to
characterize tremulous movements at various joints are likely to fail due to the variability and
complexity of tremor and the difficulty in accurately separating multi-joint, whole arm
movements. Thus, the lack of adequate tremor assessment tools and poor injection guidelines
have limited the use of BoNT-A for ET and PD tremor.27,69,75 Ultimately, it is of great
interest to improve the efficacy and tolerability of BoNT-A therapy by applying kinematic
tremor biomechanics captured from each individual in order to better target BoNT-A to
muscles contributing to the overall joint tremor.

1.4. Summary
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The focus of this thesis is to apply commercially available motion sensor technology to
measure the variation in joint tremor amplitude brought out by various scripted tasks to
generate unique, correlational tremor profiles of PD and ET tremor types. Kinematic tremor
assessments employing rest and postural paired tasks is simple, quick and could be translated
to the clinic setting as a diagnostic aid, The use of multi-sensor kinematic technology
addresses the significant unmet need in tremor therapy by pairing BoNT-A injections with
individualized, multi-joint movement patterns. This combination has shown to alleviate
tremor severity, improve the functional efficacy of BoNT-A while limiting the likelihood of
dose-dependent weakness perceivable by patients.
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2. Differentiating parkinsonian tremor and essential tremor by the variation in tremor
amplitude denoted in paired rest, postural and weight-bearing tasks
2.1. Introduction
Since tremor is the most common movement disorder, there are many different types of
tremor that are often mistaken for one another.1 Most errors in interpretation are essential
tremor (ET) misdiagnosed as parkinsonian tremor, although distinguishing other tremors is
also difficult.2 Both ET and Parkinson’s disease (PD) tremors have overlapping features that
lead to high misdiagnosis rates which commonly occurs when other parkinsonian symptoms
such as bradykinesia, rigidity and postural instability are not evident.3 Such misdiagnosis can
have a significant impact on the patient’s state of mind. ET is a heterogeneous condition
characterized by a postural or action tremor that typically affects both of the upper limbs (at
least 95%) and less commonly the head (34%), voice (12%), and lower extremities (30%).3
The location, amplitude and frequency of tremor along the whole arm vary among patients
and while the condition is considered “benign”, it frequently results in significant physical
and psychosocial disability and many ultimately seek symptomatic treatment. Parkinson’s
disease (PD) patients also experience tremor which can be quite bothersome as more than
75% of patients develop tremor over the disease course. Classic PD tremor is typically
asymmetrical, unilateral, and occurs at rest affecting the fingers, hand and wrist. However,
PD tremor may be bilateral, affect the proximal upper limb and manifest itself during
voluntary movements, although with delayed onset. Current literature reports that frequencytolerance distinguishes between ET and PD tremor.4 However, it is unknown how variations
of clinically relevant static tasks such as rest and posture positions (e.g. forearm is resting
fully pronated versus supinated) modulate tremor amplitude and the composition of tremor
along the whole-arm, rather than at the wrist only.5 Additionally, it is of interest to determine
whether this information can be used to differentiate between these tremor types as current
techniques of assessing tremor heavily depend on clinical expertise, and the use of clinicianbased ratings and clinical scales.6 Individual clinical tremor ratings can vary causing poor
inter-rater reliability. Additionally, tremor rating scales contain an integer rating system (0-4)
which lacks the accuracy of a more specific quantitative approach, a necessity in the field of
movement disorders. There are many different methods of evaluating tremor but they are
often complex, unavailable, and are developed for a specific tremor type.6
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The use of gyroscopes, accelerometers, and magnetometers have advanced the field of
objective movement in all facets of everyday life but particularly in monitoring whole-body
movements in patients with movement disorders such as PD.7 Such devices can measure
overall tremor severity and can aid clinicians in understanding the variability in tremor when
the patient is outside the clinic setting.7-9 However, these medical devices are not necessarily
regulated by the Food and Drug Administration (FDA) to assure effectiveness, safety,
accuracy and ease of use of such medical devices and mobile device apps. Thus, caution is
required as such wearable devices do not provide accurate and diagnostically relevant
information and translation to the clinical setting may not be easy.7 Thus, the purpose of this
study is to utilize objective measures of joint tremor, by goniometers and a torsiometer, to
explore the relationship of tremor amplitude, composition, and variability between different
rest, postural and weight-bearing scripted tasks in ET and PD individuals. This study aims to
determine whether changes in tremor by task variation are exclusive to either ET or PD, as
this would be a novel and simple way to distinguish these tremor types in a clinical setting.

2.2. Methods1,2
2.2.1. Study timeline
This single-centre, pilot study recruited a convenience sampling of 24 ET participants and 28
PD participants from the London Movement Disorder Centre who completed a single study
visit. The study visit consisted of clinical scales and kinematic tremor measurements.
Medication was not withheld from participants during the assessment. The tremor dominant
limb was assessed in all participants.

2.2.2. Study Criteria

1

A version of parts of this chapter has been published (Samotus O, Rahimi F, Lee J, Jog M (2016) Functional
Ability Improved in Essential Tremor by IncobotulinumtoxinA Injections Using Kinematically Determined
Biomechanical Patterns – A New Future. PLoS ONE 11(4): e0153739. doi: 10.1371/journal.pone.0153739
2
A version of parts of this chapter has been published (*Rahimi F, *Samotus O, Lee J, et al. Effective
management of upper limb parkinsonian tremor by BoNT-A injections using sensor-based biomechanical
patterns. Tremor Other Hyperkinet Mov. 2015; 5. doi: 10.7916/D8BP0270)
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This study protocol was approved by Western University Health Sciences Research Ethics
Board (REB#18445) on March 28, 2012 (see Appendix A for the approval letter and
Appendix B for the full REB protocol). Participants provided written consent to participate in
this study by signing the study’s consent form. The ethics committee provided full board
approval for this study protocol and consent procedure was approved as required in the
consent documentation checklist, submitted with the full study protocol. All ongoing and
related trials for this drug/intervention are registered (ClinicalTrials.gov Identifier:
NCT02427646).

2.2.2.1.

Study criteria for ET participants

The inclusion criteria consisted of male and female participants, aged 18 to 80 years
diagnosed with ET with upper limb tremor as their primary and most bothersome symptom
for at least two years, BoNT-A naïve, on stable medication management for a minimum of
six months prior to study enrolment, with none withheld or adjusted during the study. At
enrollment, participants were either stable on their anti-tremor medications, unable to tolerate
oral medications, or unwilling to comply due to side effects. Exclusion criteria were those
who had a history of stroke, contraindications per the BoNT-A monograph, pregnancy, and
existing pharmacological therapy with tremor-inducing side effects (e.g. lithium, valproate,
steroids, amiodarone, or beta-adrenergic agonists such as salbutamol).

2.2.2.2.

Study criteria for PD participants

Inclusion criteria were: consenting male and female participants diagnosed with PD by UK
Brain Bank Criteria with H&Y stage 1-3 disease, aged 18 to 80 years, having tremor as their
most bothersome and important symptom while on stable medication management for at least
six months prior to enrolment, with none withheld or adjusted during the time of the study,
and BoNT-A naïve. Participant criteria excluded those who had a history of stroke,
contraindications per the BoNT-A drug monograph, pregnancy, and existing
pharmacological therapy with tremor-inducing side effects (e.g. lithium, valproate, steroids,
amiodarone, or beta-adrenergic agonists such as salbutamol).
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2.2.3. Kinematic assessment
2.2.3.1.

Kinematic experimental tasks

PD and ET participants performed a series of scripted, paired tasks designed to study the
effect of task variation on upper limb tremor. Paired tasks involved two rest positions
(focusing on flexion/extension (F/E) and pronation/supination (P/S) movements), two
postural positions (focusing on F/E and radial/ulnar (R/U) movements), and two weightbearing tasks to simulate daily activities such as eating and drinking (Figure 2-1). These tasks
were completed thrice in series and 20 seconds were allotted for each task. Rest tasks,
denoted “Rest-1” and “Rest-2” were performed with a distraction (Figure 2-1a-b). Postural
tasks involved the participant to extend both arms outstretched in front of their body with
palms facing downwards or inwards, denoted “posture-1” (arms outstretched, palms down)
and “posture-2” (palms facing inwards; Figure 2-1c-d). Weight-bearing tasks involved the
participant holding an empty cup, “load-1”, or a cup with a 1-lb weight, “load-2”, with their
shoulder abducted, elbow flexed with the cup held in front of the body or below the mouth
(Figure 2-1e-f).
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Figure 2-1. Images depicting three static, scripted task variations during rest, posture,
and weight-bearing paired tasks.
(a) Rest position (“rest-1”) with relaxed forearm in lap measuring F/E wrist movements. (b) Rest
position (“rest-2”) with arm supported measuring P/E movements. (c) Postural position (“posture-1”)
with shoulders flexed at 90° with arms extended anteriorly and pronated (palms facing downwards).
(d) Postural position (“posture-2”) position with shoulders flexed at 90° with arms extended
anteriorly, palms facing inwards. (e) Functional task (“load-1”) with the participant holding an empty
cup in front of body with elbow and proximal arm unsupported (f) Functional task (“load-2”) holding
a cup with a one-pound weight in front of body with elbow and proximal arm unsupported.

31

2.2.3.2.

Kinematic sensor set-up

Figure 2-2 displays the placement of a total of four motion recording sensors attached over
the wrist, elbow, and shoulder arm joints. Motion sensor devices were placed over each the
forearm, wrist, elbow and shoulder joints capturing tremor severity in angular root mean
square (RMS) amplitude simultaneously in multiple degrees of freedom (DOF).
Electrogoniometers measured wrist tremor, by angular position, in two degrees of freedom,
F/E and R/U deviations (SG150, Biometrics Ltd). Wrist tremor in the P/S plane was
measured by a torsiometer placed on the dorsal surface of the forearm (Q150, Biometrics
Ltd.). Thus, the torsiometer provided the third angular degree of freedom of rotational motion
about the wrist. Elbow tremor was captured an electrogoniometer in one degree of freedom,
F/E. An electrogoniometer placed on the shoulder measured two degrees of freedom, F/E and
abduction/adduction (Abd/Add). Internal/external shoulder rotation was not feasible to
kinematically measure. Sensors were attached using 3M hypoallergenic micropore medical
grade tape (Ref#: 1530–1).
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Figure 2-2. Images depicting sensor placement.
Placement of Biometric® motion sensors along arm: shoulder electrogoniometer, elbow
electrogoniometer, wrist electrogoniometer, accelerometers placed on forearm, hand and third finger.

Sensor calibration was completed with the forearm supported and with the hand fixed against
a vertical plane in neutral F/E, R/U, and P/S positions, and was held for five seconds.
Additional sensor calibration was performed with the participant’s arm held straight while
standing, elbow extended with fingers pointing down for five seconds. Motion sensor data
was collected at 1500Hz by TeleMyo™ 2400T G2 and PC interface (MyoResearch XP
Master Edition 1.08.09, Noraxon®). Recordings at each joint were mutually exclusive with
each sensor recording data only from a particular joint.

2.2.3.3.

Kinematic tremor analysis output
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Custom written software in MatLab® (R2011a) processed raw angular signal data captured
by the motion sensors.10 The interpreted data displayed tremor severity, as total angular RMS
amplitude, in each DOF during each task in each arm joint. The software provided a
percentage contribution of the directional movements in the wrist and shoulder joint as
further tremor segmentation was not achievable at the elbow that deviates only in F/E DOF.

2.2.4. Statistical analyses
IBM® SPSS version 20 was the statistical program used to investigate the relationship of
tremor severity in ET and PD across paired scripted tasks. Each task was performed thrice in
series per kinematic recording session. The mean angular RMS tremor amplitude across three
trials for each task per study visit was log-transformed as tremor amplitudes generated
skewed distributions. The dispersion of the data from the mean was displayed as standard
deviation of the population. Pearson’s product-moment correlation was conducted to observe
the relationship of joint tremor amplitudes between paired tasks and across non-paired tasks
within ET and PD populations, and between ET and PD population groups. A paired t-test
was performed to assess the statistical difference in tremor amplitudes across tasks within ET
and PD populations. An independent t-test was conducted to determine whether a correlation
(r value) was statistically significantly different between ET and PD groups. Similar
statistical tests were conducted on the percent contribution of tremor in each DOF to the
overall wrist tremor.

2.3. Results
2.3.1. Study demographics
The demographics of the ET participants are found in Table 3-1 in section 3.3.1 in Chapter 3.
The demographics of the PD participants are found in Table 4-1 in section 4.3.1 in Chapter 4.

2.3.2. Effect of task variation on joint tremor severity
2.3.2.1.

Essential Tremor
34

Mean tremor amplitude correlations were substantial in each joint across tasks (Figure 2-3).
Mean tremor amplitude at the wrist, elbow or shoulder during “rest-1” or “load-1” led to a
strongly correlated increase in tremor amplitude in the paired task (“rest-2” or “load-2”;
r>0.5, p<0.05). However, this was not evident between “posture-1” and “posture-2” tasks
indicating postural task variation significantly modulates tremor amplitude in all joints. A
paired samples t-test revealed mean wrist tremor amplitude in tasks “posture-1” and “load-1”
was significantly increased by 61.6% in “posture-2” [t(23)=2.81,p=0.01,95%CI -0.57 to 0.87
log-RMS degrees] and by 20.9% in “load-2” [t(23)=2.912,p=0.008,95%CI -0.31 to -0.05 logRMS degrees], respectively, indicating forearm supination and additional weight increases
wrist tremor amplitude in ET. Mean wrist tremor amplitude from tasks “posture-2” and
“load-2” was statistically, strongly correlated [r(24)=0.60,p=0.002] though was not
statistically different [t(23)=0.61,p>0.05,95%CI -0.32 to 0.57 log-RMS degrees] indicating
these two arm positions produced similar wrist tremor severities.

Task variation (paired tasks) did not significantly change elbow tremor amplitude. However,
mean elbow amplitudes during “posture-1” and “posture-2” were weakly correlated, as
similarly seen in the wrist joint. Interestingly, mean elbow tremor amplitude in “posture-2”
compared to both load tasks were strongly correlated and following a paired samples t-test,
mean elbow tremor amplitude during “posture-2” was significantly lower by 58.3%
compared to “load-2”, indicating weight increases elbow tremor but not wrist tremor
[t(23)=1.408,p=0.17,95%CI -0.30 to 0.06]. Mean shoulder tremor amplitudes did not
significantly change between all tasks. However, tremor amplitude was strongly correlated
between rest tasks, between load tasks, and between “posture-2” and load tasks, as seen in
both the wrist and elbow joints.
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Figure 2-3. Pearson’s coefficient correlation heat map of mean tremor amplitude in the
wrist (top), elbow (middle) and shoulder (bottom) across all scripted tasks in ET
participants.
Mean wrist and elbow tremor amplitudes during both rest tasks were significantly correlated
(Figure 2-4). In addition, mean elbow tremor amplitude was strongly correlated [r=0.718;
p<0.0005] to wrist tremor amplitude in “posture-1” (when the elbow is fully extended) yet
was weakly correlated to wrist tremor during “posture-2” [r=0.23, p=0.342] and both load
tasks [r=0.27 and r=0.24, p>0.05]. Tremor amplitude captured at the wrist and elbow during
“posture-2” and both load tasks (with elbow flexion involvement) were strongly correlated (r
values range from 0.665 to 0.891), suggesting a significant linear relationship between wrist
and elbow tremor measured during tasks involving elbow flexion when the limb is
unsupported and held against gravity.
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Figure 2-4. Pearson’s coefficient correlation map of mean wrist and elbow tremor
amplitudes across all scripted tasks in ET participants.
2.3.2.2.

Parkinson Disease

In PD participants, there was a strong, positive correlation of wrist tremor amplitude between
paired tasks [r(24)>0.6,p<0.0005] (Figure 2-5). A paired samples t-test revealed the mean
wrist tremor amplitude in “rest-1” was significantly increased by 69.7% in “rest-2” task
[t(23)=2.869,p=0.009,95%CI -0.40 to -0.06 log-RMS degrees]. However, tremor amplitude
was highly correlated yet was not significantly different between postural and load paired
tasks (p>0.05). This signified that task variation when the arm is at rest significantly
modulated wrist tremor which was not observed during postural or weight-bearing paired
tasks. Observing mean wrist tremor across all tasks, mean wrist tremor during “rest-2” and
“posture-1” was strongly correlated (r=0.616;p=0.001) and a paired samples t-test revealed
mean wrist tremor amplitude in “rest-2” was significantly reduced by 42.4% in “posture-1”
[t(25)=2.132,p=0.043,95%CI 0.01 to 0.34 log-RMS degrees] and by 46.6% in “load-2” task
[t(25)=2.661,p=0.013,95%CI 0.07 to 0.54 log-RMS degrees]. This indicated that voluntary
wrist extension observed in “posture-1” (holding palms facing downwards) and in “load-2”
(when gripping a weighted cup) significantly reduced wrist tremor.

Mean elbow tremor amplitude between paired tasks was strongly and statistically correlated
(Figure 2-5). Mean elbow tremor in “rest-2” was significantly increased by 45.5% when
compared to tremor amplitude during “rest-1” task [t(24)=2.400,p=0.025,95%CI -0.27 to 0.02 log-RMS degrees], similarly observed in the wrist joint; however mean elbow tremor
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amplitude in “rest-1” was significantly increased by 54.9% in “load-1”
[t(24)=2.198,p=0.038,95%CI -0.45 to -0.01 log-RMS degrees], but was not significantly
different in “load-2” [t(24)=-1.972,p=0.060,95%CI -0.48 to 0.01 log-RMS degrees]. This
signifies that elbow flexion in “load-1” increases elbow tremor severity and additional weight
reduces elbow tremor severity, when compared to tremor severity at rest (when arm is fully
supinated in lap). There were no correlations or significant differences in mean shoulder
tremor amplitude across all tasks.

Figure 2-5. Pearson’s coefficient correlation heat map of mean tremor amplitude in the
wrist (top), elbow (middle) and shoulder (bottom) across all scripted tasks in PD
participants.
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Mean wrist and elbow tremor amplitudes were strongly correlated between all posture and
load tasks and between “rest-1” and “rest-2” tasks (Figure 2-6).

Figure 2-6. Pearson’s coefficient correlation map of mean wrist and elbow tremor
amplitudes across all scripted tasks in PD participants.
2.3.2.3.

Comparing Essential Tremor and Parkinson Disease profiles

Mean wrist tremor amplitude was significantly higher in PD participants than ET participants
during “rest-1”, “rest-2” and “posture-1” tasks (Figure 2-7). There was no significant
difference in wrist or elbow tremor amplitudes captured in PD and ET participants during
“posture-2”, “load-1” and “load-2” tasks.
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Figure 2-7. Mean joint tremor amplitude in ET and PD participants quantified in each
scripted task. Error bars represent standard deviation of population.
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Error bars represent standard deviation of population. Black brackets indicate between group
comparisons; blue brackets indicate within ET group comparisons; red brackets indicate
within PD group comparison. * represent p-value < 0.05 and ** represent p-value < 0.01
following an independent samples t-test (between groups) or a paired samples t-test (within
group).
No significant correlations were found in wrist or shoulder tremor amplitudes between ET
and PD participants across all tasks (Figure 2-8). However, mean elbow tremor amplitude
during “posture-1” in ET participants was moderately correlated to mean elbow tremor
amplitude in tasks “posture-2” (r=0.45) and “load-1” (r=0.42) and was not correlated in
“load-2” in PD.

Figure 2-8. Pearson’s coefficient correlation map of mean tremor amplitude at the wrist
(top), elbow (middle) and shoulder (bottom) across all scripted tasks between ET and
PD participants.
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2.3.3. Effect of task variation on wrist tremor composition
In ET participants, mean percent contribution of wrist tremor in the F/E DOF was
significantly increased from 27.4±6.4% in “rest-1” to 33.5±8.7% in “rest-2” (Figure 2-9).
Additionally, the mean F/E percent contribution was significantly reduced in “posture-2” and
“load-2” compared to “posture-1” and “load-1”, respectively. However, mean percent
contribution of tremor in the P/S and R/U DOFs did not significantly change as a result of
task variation.

Figure 2-9. Task variation significantly modulated the mean percent distribution of
wrist tremor in the F/E DOF between all paired tasks in ET participants.
P-values <0.05 represents the statistically significant mean difference.
Likewise in PD participants, the mean percent contribution to the total tremor in the F/E DOF
significantly increased in “rest-2” and was reduced in “posture-2” and “load-2” tasks when
compared to “rest-1” task (Figure 2-10). In addition, the amount of tremor originating from
the R/U DOF significantly increased from 22.8±11.7% in “posture-1” to 28.8± 13.9% in
“posture-2” [t(25)=3.628,p=0.001,95%CI -9.4 to -2.6], which was not observed in ET
participants.
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Figure 2-10. Task variation significantly modulated the mean percent distribution of
wrist tremor in the F/E DOF between all paired tasks in PD participants.
P-values <0.05 represents the statistically significant mean difference of an independent
samples t-test.

2.4. Discussion
This study demonstrated that multi-sensor kinematics quantified joint tremor amplitude to
generate different tremor profiles based on the effect of paired tasks that alter limb
positioning. As literature suggests there is a peripheral component of tremor that lies within
the adrenergic mechanisms in muscle spindles, this study applied task variation to understand
how modulating limb positioning can influence tremor amplitude and tremor distribution in
ET and PD participants.14,15 Detailed clinical examinations focusing on specific tremor
features including amplitude, frequency, distribution and pattern, and associated clinical
history can aid in further distinguishing between these two diseases.11 However, studies of
quantitative tremor analysis involving surface EMG and accelerometry have concluded that
tremor frequency ranges between ET and PD are somewhat different yet there is considerable
overlap.12 Furthermore, PD and ET tremor amplitudes are similar during most positions and
surface EMG studies identify patterns in PD and ET cases but these methods do not
distinguish tremor types due to too much variability.11,12 Thus, evaluation of tremor in
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different limb postures has proven to be imperative in diagnostic studies as tremor features
are strongly influenced by the method of measurement.13

Within ET participants, there was a significant and strong correlation of joint tremor
amplitudes, either in the wrist, elbow or shoulder, between rest tasks and between load tasks.
However, this was not observed between posture tasks, a distinctive feature of ET (Figure 23). Furthermore, the amplitude of wrist tremor during “posture-1” in PD was significantly
higher than in ET participants, which was similar to a previous report by Jankovic in
1999.11,16 In PD participants, mean joint tremor amplitude was significantly correlated
between postural and load tasks but this was not observed between rest tasks, contrasting ET
(Figure 2-5). Additionally, the effect of rest task variation significantly alters PD tremor in
the wrist and elbow joint, though this was not observed in ET participants. Thus, not only
does the latency of tremor onset when assuming horizontal postures differentiate PD and ET
tremor types,16 but also this study demonstrated that postural or rest task variations
influenced tremor amplitudes in ET or PD participants, respectively.

Burne J et al reported that PD and ET tremor amplitudes were similar in most positions.12 In
accordance with past studies, mean tremor amplitudes in the wrist and elbow during tasks
“posture-2”, “load-1” and “load-2” were not statistically different and were strongly
correlated between ET and PD participants (Figure 2-7). It was also interesting to observe
that mean wrist tremor severity during “posture-2” and in both load tasks was strongly
correlated to mean elbow tremor amplitude in both ET and PD; however, a strong correlation
between wrist and elbow tremor amplitudes in “posture-1” was observed in PD but not in ET.
This suggested that ET may be more susceptible to peripheral reflex modification than PD
tremor when the limb is held in postural positions.13

Past studies observed variation of tremor amplitude during weight-bearing tasks to
distinguish between pathological tremors and physiological tremor; however the effect of
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weight-loading has not been utilized to distinguish ET and PD tremor types.11,13,17 In PD,
mean elbow tremor amplitude during “rest-1” was significantly lower than in “load-1”
however mean elbow tremor amplitudes in “rest-1” and “load-2” tasks were statistically
similar. On the other-hand in ET, mean elbow tremor amplitude was significantly greater in
“posture-2” and in both load tasks when compared to “posture-1” and both rest tasks. This
emphasises that greater elbow flexion increased elbow tremor in PD and ET patients but
added weight reduced elbow tremor amplitude in PD and significantly increased mean elbow
tremor amplitude in ET. Interestingly the increase in ET elbow tremor during “load-2” was
not accompanied by a significant increase in wrist tremor however this was not the case for
PD participants. Thus, this demonstrated that tremor amplitude in ET was more sensitive to
the effects of change to the mechanical state of the limb.17

In both PD and ET participants, there was a significant change in the amount of tremor
originating in the F/E DOF due to task variation (between paired tasks). In addition to change
in percent contribution from the F/E DOF, a significant reduction in wrist tremor originating
in the R/U DOF was observed in PD between postural tasks. A possible explanation to the
significant change seen in F/E DOF as opposed to P/S DOF may be due to the greater use of
wrist extensors/flexors during tasks such as: assuming palms facing downwards with arms
outstretched in “posture-1”, gripping a weighted cup close to chest in “load-2”, and restricted
wrist extensor range of motion in “rest-1” task. The analysis of the percent contribution of
tremor was not considered a distinctive element of PD or ET and hence may not be
diagnostically useful in the clinic setting. However, such joint tremor segmentation would be
advantageous for individualizing focal therapy of tremor with BoNT-A injections.10 In
addition, this study concluded that the segmentation of shoulder tremor would also be
beneficial for BoNT-A therapy as shoulder tremor analysis cannot be used to distinguish
between ET and PD tremor types.

2.5. Conclusion
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This thesis chapter demonstrated how task variation and limb positioning can influence
unique ET and PD tremor profiles. These tremor profiles can be used to distinguish between
ET and PD tremor types. The use of objective measures to quantify the relationship of wrist
and elbow tremor amplitudes between paired tasks is a simple and easy method that can be
applied in the clinic setting in order to aid in improving diagnostic certainty and
personalizing treatments.
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3. Functional ability improved in Essential Tremor by incobotulinumtoxinA injections
using kinematically determined biomechanical patterns – A made to measure
therapy3
3.1. Introduction
One of the most prevalent movement disorders is essential tremor (ET), affecting 4.6% of
people aged 65 and older.1 ET is visually characterized by persistent, bilateral, mainly
symmetrical postural or kinetic tremor involving distal and/or proximal arm muscles. The
severity of ET gradually increases over time that may cause significant difficulty with daily
tasks such as eating, grooming and other fine motor tasks. Functional disability due to tremor
greatly affects the quality of life in patients who subsequently seek treatment. The most
effective oral medications to symptomatically treat mild or moderate ET are primidone, an
anticonvulsant, and propranolol, a beta-adrenergic receptor antagonist.2 Although these
agents reduce tremor amplitude by approximately 50%, they provide limited functional
benefit and adverse side effects such as dizziness, fatigue, and bradycardia commonly occur.3
In addition, 30% of patients have no therapeutic benefit leaving a large population with
severe ET untreated.4 Surgical therapy with thalamotomy or unilateral/bilateral thalamic deep
brain stimulation is safe, although possibly effective (Level C recommendation) and is
performed in patients under the age of 75 where post-operative device programming remains
unclear.2,5 Thus, a new approach for treating debilitating tremor is still a significant unmet
need.

Botulinum neurotoxin type A (BoNT-A) intramuscular injections are commonly used to treat
various movement disorders, such as focal dystonias, and may provide modest beneficial
effects in essential tremor patients who are unresponsive to conventional
pharmacotherapies.6,7 Prior studies have reported that BoNT-A therapy reduces the severity
of postural tremor with minimal improvements in clinical scores.8-10 Despite this modest
clinical benefit, BoNT-A therapy has not been widely adopted due to risk of significant hand

3

A version of this chapter has been published (Samotus O, Rahimi F, Lee J, Jog M (2016) Functional Ability
Improved in Essential Tremor by IncobotulinumtoxinA Injections Using Kinematically Determined
Biomechanical Patterns – A New Future. PLoS ONE 11(4): e0153739. doi: 10.1371/journal.pone.0153739)
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and wrist weakness causing functional limb impairment.7 The primary drawback of these
prior studies was utilizing a rigid dosing regimen which did not individualize and target
appropriate muscles nor were appropriate BoNT-A dosages applied which failed to provide
functional benefit. The fixed dosing regimen considers that tremor is similar across patients
and across joints thereby defeats the advantage of using BoNT-A as a targeted and
individualized focal therapy. The variation in tremor dynamics is considerable and multiple
joints, wrist, elbow and shoulder, can be involved to differing degrees making visual
assessments a significant challenge. Hence, it is clear that proper identification of the
dynamics of the tremulous joints would allow individualization of muscle selection necessary
to optimize injection pattern and outcomes.

Subjective tremor assessment tools, such as clinical rating scales are inaccurate methods of
clinical evaluation that are not specific to tremor type. Characterization of tremor by
kinematic methodology is objective and superior to visual inspection alone, a challenging
task for a clinician. Preliminary work shows that identification of tremulous joints and
muscles by accelerometers and by surface EMG can reduce the occurrence of muscle
weakness.11 Minimization of dose-dependent weakness is achievable by utilizing such
objective methods to deliver individualized injection patterns.12,13

Multi-sensor technology has been well established, is becoming very affordable and is
capable of characterizing tremor at the wrist, elbow, and shoulder.14,15 Objective measures of
the severity and direction of tremulous movements along the whole limb can be used for
selecting injection sites and BoNT-A dose per muscle. Recent work in treatment of Parkinson
disease (PD) tremor using methodology discussed in this paper has been successful.16
However, clinical and biomechanical features of PD tremor are distinctly different from
those seen in ET. In addition, the postural and kinetic nature of ET tremor results in different
joint biomechanics and the individualization of injection patterns based upon kinematics are
considerably different than in PD tremor. The current paper shows results of a first of its kind
study use a kinematically guided, individualized, multi joint upper limb injection approach to
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determine the efficacy and safety of incobotulinumtoxinA as a focal treatment in the longest,
38-week duration open label study involving ET participants.

3.2. Methods
3.2.1. Study Timeline
This single-centre, single-injector, open label (Health Canada CTA# 178589) pilot study
recruited a convenience sampling of 24 ET participants from the London Movement Disorder
Centre who completed six study visits at weeks 0, 6, 16, 22, 32, and 38 and were injected at
weeks 0, 16, and 32. Assessments were carried out at all visits and peak dose effects were
measured at 6 weeks after each visit. As prior studies have stated that BoNT-A peak effect is
evident approximately 2 weeks to 8 weeks post-injection, the designated time-point for a
follow-up visit occurred 6 weeks post-injection to encompass the peak effect.17 Treatments
were administered every 4 months instead of every 3 months, which is typically followed in
the clinic setting, to incorporate a BoNT-A washout period of 1 month.17 Each study visit
consisted of clinical scales and kinematic tremor measurements. Medication was not
withheld from participants during study visits. The tremor dominant limb was injected with
incobotulinumtoxinA (0.5 mL of saline per 100 unit vial) using needle electromyographic
(EMG) guidance (1” long 30 g injectable EMG needle using a Clavis® portable EMG
machine.
3.2.2. Study Criteria
This study protocol was approved by Western University Health Sciences Research Ethics
Board (REB#18445) on March 28, 2012 as a clinical phase IIb pilot study, see Appendix A.
The letter of information for this study is located in Appendix B. The power calculation
provided in the ethics study protocol submission suggested a target sample size of 35 ET
participants, though this calculation was based on literature which did not incorporate
kinematics or any objective data for guiding BoNT-A injections for tremor. As this is an
open-label pilot study with no randomization, a convenience sampling was reported for those
that were screened (n=25) and for those that participated in the study (n=24). Additionally,
the duration of the study stated in the approved protocol is for a 96-week study over thirteen
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study visits. However, the current results were significant at the timeline reported in the
manuscript (six study visits over 38 weeks) as serial BoNT-A for upper limb tremor have
been sparsely reported in this manner. Participants provided written consent to participate in
this study by signing the study’s consent form. The ethics committee provided full board
approval for this study protocol and consent procedure was approved as required in the
consent documentation checklist, submitted with the full study protocol. Registration with a
clinical trial registry was not a requirement for ethics approval to perform the study at this
institution. The authors confirm that all ongoing and related trials for this drug/intervention
are now registered (ClinicalTrials.gov Identifier: NCT02427646). See Figure 3-1 for the
CONSORT flowchart. The inclusion/exclusion criteria stated in Chapter 2, section 2.2.2.1
was used in this study.

51

Figure 3-1. CONSORT flow diagram displaying the progress of the study’s design.
3.2.3. Kinematic Assessment
3.2.3.1.

Kinematic Experimental Tasks

Kinematic assessments were conducted when participants were on their anti-tremor
medications as this state was deemed to be best determined after taking into account the
optimal medication response. The sensor calibration tasks and a series of two postural and
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two weight-bearing scripted tasks, previously described in Chapter 2 (Figure 2-1c-f), were
performed by each participant while seated with motion sensor devices placed over each arm
joint, as pictured in Figure 2-2 in Chapter 2. The same custom-written Matlab® code,
described in Chapter 2, was used to extract angular position and angular tremor amplitude in
RMS degrees from each DOF per arm joint.

3.2.4. Injection Determination
Custom written software in MatLab® (R2011a) processed raw angular signal data captured
by the motion sensors was analyzed using the same methodology as in Chapter 2, section
2.2.3.3. The interpreted data displayed tremor severity, as total angular RMS amplitude, in
each DOF during each task in each arm joint that was reviewed by a clinician prior to
injection. The software provided a percentage contribution of the directional movements.
Based upon the experienced clinician’s best judgment, a preselected total dose based on
tremor amplitude was divided using the percentage contribution data and was allocated to
appropriate muscles for injection. Muscles selected for injection were based upon wellknown anatomical basis of movement at each joint. Dosages for subsequent injection visits
were based upon comparisons of kinematics at that visit to prior kinematic data. This
approach allowed the experienced clinician to use the kinematic data to tailor the injections at
each joint and to ensure the most appropriate muscles were selected, making the approach
generalizable in the experienced clinician’s hands.

3.2.5. Clinical Scale Assessment
Validated tremor severity and functional rating scales were used as primary endpoints for
measuring efficacy and safety of incobotulinumtoxinA treatments. Participants completed the
Fahn-Tolosa-Marin (FTM) Scale18 consisting of parts A-C rating tremor severity, writing and
functional disability caused by tremor, and the Quality of Life for Essential Tremor
(QUEST)19 questionnaire encompassing 30-items rating physical, psychosocial,
communication, hobbies/leisure, and work/finance, the response to the 30-items, ranging
from never = 0, rarely = 1, sometimes = 2, frequently = 3, and always = 4, were tallied for
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each participant for each study visit. The assessor monitored strength in participant’s fingers,
distal, and proximal arm muscles by manual muscle testing (MMT), and by maximal grip
strength, using a dynamometer.20 Muscle weakness reported by participant was assessed
using a Likert scale (ranging from 0 = no weakness to 4 = severe weakness in whole arm).
The movement disorder neurologist, blinded to prior results, assessed tremor using UPDRS
(items 20 and 21) during injection visits.21 The FTM, QUEST, MMT and UPDRS scales are
displayed in the Appendix sections C-F.

3.2.6. Statistical Analyses
IBM® SPSS® statistics version 20 was used to analyze both kinematic and clinical data
using one-way repeated measures analysis of variance (ANOVA) using confidence intervals
of 95% (ɑ = 0.05) with post hoc Bonferroni corrections for multiple comparisons performed
across all time-points. Missing of random value analysis was conducted for all independent
variables to ensure incomplete data sets were missing completely at random and multiple
imputation method was not utilized for this dataset. Participant clinical rating scores from
each time-point were analyzed by mean and dispersion of the data from the mean, standard
deviation of the population. The mean angular RMS tremor amplitude across three trials for
each task per study visit was log-transformed as tremor amplitudes generated skewed
distributions. Acceleration values were computed by averaging the acceleration in X-axis, Yaxis and Z-axis for each task per participant at a visit. Each task was performed thrice in
series per kinematic recording session. The means from each clinical rating scale and from
the kinematic tremor analyses that met criteria were tested for normality using the ShapiroWilk test and z-score for skewness and kurtosis. The means which met criteria for parametric
analysis underwent parametric ANOVA tests to investigate the presence of significant
changes between time-points. If the means did not meet criteria for parametric analysis, the
Friedman ANOVA test was conducted. A p-value < 0.05 for the Mauchly’s test of sphericity
indicated that the assumption of sphericity had been violated. The Greenhouse-Geisser
correction of this bias was used when the estimated epsilon (ε) was less than 0.75 or by the
Huynh-Feldt correction if estimated epsilon (ε) was greater than 0.75. Partial eta-squared
(partial η2) was reported as an estimate of the population effect size.
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3.3. Results
3.3.1. Participant Demographics
Demographics and baseline clinical rating scores of the 24 ET participants are summarized in
Table 3-1. 25.0% of participants (6/24) were being treated with primidone (mean dose of 125
mg/day). 4.2% of participants (1/24) withdrew following week 22 due to a myocardial
infarction, unrelated to the study intervention. At week 38, 4.2% of participants (1/24) were
withdrawn due to failed attendance and 4.2% of participants (1/24) withdrew due to
unwanted weakness.

Table 3-1. ET participant demographics and baseline UPDRS, QUEST and FTM parts A to
C scores
Injected Limb
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Part
A
Rest
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(lbs)
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1

M

76

175

Primidone
(125 mg)

R

R

31

1

3

2

2

3

6

2

14

2

F

74

165

Primidone
(125mg)

R

R

27

1

2

1

2

2

4

1

11

3

M

67

270

N/A

R

R

39

1

3

2

4

2

4

1

14

4

M

76

223

Primidone
(125 mg)

R

R

49

2

2.5

1

3

3

6

2

20

5

M

78

220

Primidone
(125mg)

R

R

27

0

3

0

3

3

2

1

17

R

R

30

2

2.5

2

3

3

5

2

22

Injec
ted
Limb

6

M

84

225

Propranolo
l (180mg),
primidone
(250mg)

7

F

64

120

N/A

R

R

49

0

3.5

2

3

3

5

3

21

8

F

71

140

N/A

R

R

48

1

3.5

1

4

0

6

3

10

55

9

M

61

167

N/A

R

R

61

0

2.5

2

3

3

4

3

18

10

F

82

120

N/A

R

L

22

0

3

0

0

3

8

2

15

L

L

49

0

3

3

3

3

7

4

17

11

F

68

205

Quetiapine
(400mg),
Omeprazol
e (40mg),

12

M

85

221

N/A

R

R

5

0

2.5

3

2

2

5

1

14

13

F

51

160

N/A

R

R

40

1

2

1

1

0

3

2

13

14

F

66

300

N/A

R

R

61

0

3

1

3

1

7

3

23

15

F

78

155

N/A

R

R

47

0

2

2

2

1

2

2

14

16

F

65

270

N/A

R

R

42

0

3

1

2

1

4

2

12

17

M

80

175

N/A

R

R

76

0

3.5

0

3

2

8

4

29

18

F

80

130

N/A

R

R

64

1

2

1

2

1

2

2

17

19

M

61

270

N/A

R

R

44

0

2

2

2

1

2

1

13

20

F

73

200

N/A

R

R

22

0

2

2

2

1

2

1

12

21

M

84

175

N/A

R

R

39

0

2

0

1

2

8

1

20

22

M

59

227

N/A

R

R

31

0

2

1

1

1

2

1

11

23

M

71

237

N/A

L

L

30

0

3

0

3

2

4

2

19

24

M

73

197

N/A

R

R

35

0

2

2

1

1

2

2

13

Mean
± SD

11F

72.0
±
8.9

197.8
±
50.1

-

2L

3L

40.3
±
15.8

0.4 ±
0.7

2.6 ±
0.6

1.3 ±
0.9

2.3 ±
1.0

1.8 ±
1.0

4.5 ±
2.1

2.0
±
0.9

16.2 ±
4.6

Media
n

-

73.0

198.5

-

-

-

39.5

0.0

2.5

1.0

2.0

2.0

4.0

2.0

14.5

Range
(low)

-

51.0

120.0

-

-

-

5.0

0.0

2.0

0.0

0.0

0.0

2.0

1.0

10.0

Range
(high)

-

85.0

300.0

-

-

-

76.0

2.0

3.5

3.0

4.0

3.0

8.0

4.0

29.0

SD represents standard deviation of population; items 20 and 21 represent rest and action tremor UPDRS
ratings. Weight data was collected as a correlational measure towards each individual’s total injected joint dose
and is reserved for reference for future pilot studies.
a
Medication doses represent total daily doses. Medications listed represent current, concomitant treatment at the
time of incobotulinumtoxinA therapy.

3.3.2. Selection and Administration of IncobotulinumtoxinA Treatments
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Kinematics captured severity of tremor (angular RMS amplitude) and direction of the
tremulous movement at each arm joint during each task. Figure 3-2a displays sample
kinematic tremor measures showing quantification of tremor severity in wrist, elbow and
shoulder joints (plots 1). For the wrist and shoulder joints, an additional plot calculated the
distribution of the total tremor present in each degree of freedom that every joint moves in.
Figure 3-2b demonstrates the injector’s interpretation of the kinematics showing that the
selection of the total dose was based on total tremor severity and the muscles selected were
based on the distribution of tremor at each arm joint during a task. In the example in Figure
3-2a, posture-2 task generated the most severe tremor in the wrist, and load-2 induced the
largest tremor amplitude in elbow and shoulder joints. Muscle groups, which generate these
fundamental movements, were then injected (Figure 3-2b). Thus, the kinematic measures for
all participants and their individualized injection parameters ultimately developed a dosing
table from the movement disorder’s clinical experience for each muscle and the dynamics of
the movement at each joint.
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Figure 3-2. Sample kinematic data showing (A) presence of tremor in the wrist, elbow
and shoulder joints and (B) the ideal injection parameters determined using the
kinematics with the injector’s best clinical judgement.
(A) Total tremor severity (plot 1) is displayed in angular RMS amplitude and the percent
distribution of tremulous movement (plot 2) by 3 DOFs in the wrist and by 2 DOFs in the
shoulder joint. Error bars indicate standard deviation over three trials. (B) Injector’s
interpretation of the kinematic results showing selection of total dose allocated to wrist,
elbow and shoulder muscle groups based on tremor severity and the muscles selected based
on the amount of tremor present in each degree of freedom that each arm joint moves in.
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For optimizing this therapy, a comparison in the change in tremor, measured kinematically,
from pre-injection to six weeks (BoNT-A peak effect) and to sixteen weeks post-treatment
was solely used to determine whether the BoNT-A dose or muscle sites needed to be altered.
A reduction in total tremor at the six week follow-up indicated the appropriate muscles were
targeted. An increase in BoNT-A dose was administered if the tremor could have been
reduced further, as quantified by kinematics at post-injection assessments, and no side effects
were perceived by participant (outlined in the Likert scale). A reduction in dose was
indicated by the participant experiencing side effects, muscle weakness, as rated by the
Likert scale for muscle weakness, a rating of 3+ or lower at the wrist flexion-extension and
elbow flexion-extension using manual muscle testing, which indicates weakness in injected
muscles lasting more than 4 weeks, and a significant difference in maximal grip strength
when compared to baseline scores.

Participants (n=24) were injected in their most bothersome arm. The mean total dose of
incobotulinumtoxinA administered at the first treatment (week 0) was 169.0±62.9 U in
8.8±2.0 muscles (Table 3-2). The total dose for the second treatment was increased for 50.0%
of participants (11/22), reduced for 13.6% of participants (3/22), and remained unchanged for
36.4% of participants (8/22). Between the second and third treatments, the total dose
increased for 22.2% of participants (4/18), reduced for 11.1% of participants (2/18), and
remained unchanged for 66.7% of participants (12/18). For the second treatment, the number
of injected muscle sites increased to 10.1±2.0 muscles, which remained unchanged at the
third treatment.

Table 3-2. Total injected dosage and number of muscles injected as determined by injector
across all participants
Week 0 (First Injection)

Week 16 (Second
Injection)
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Week 32 (Third
Injection)

Patient ID

BoNT-A
dose (U)

Num. of
muscles
injected

BoNT-A
dose (U)

Num. of
muscles
injected

BoNT-A
dose (U)

1

95

7

160

8

No injectiona

2

100

6

200

13

No injectiona

3

160

8

290

13

290

4

70

4

200

8

No injectiona

5

170

6

No injectiona

6

300

9

300

9

300

9

7

200

11

100

11

100

11

8

200

9

150

9

150

9

9

195

9

300

12

300

7

10

185

10

185

10

200

13

11

100

8

200

11

200

11

12

200

8

185

9

185

9

13

170

10

170

10

165

10

14

200

11

260

11

300

11

15

100

9

No injectionb

16

200

10

200

10

260

17

300

11

300

14

Withdrawnd

18

200

11

200

11

200

11

19

100

8

100

8

100

8

20

180

9

180

9

180

9

21

235

12

300

12

255

12

22

95

6

130

6

130

6

23

200

10

280

11

300

11

24

100

8

145

8

145

8

Mean ± SD

169.0 ±
62.9

8.8 ± 2.0

206.1 ± 65.8

10.1 ± 2.0

208.9 ± 71.0

10.1 ± 2.1

Dosing was in incobotulinumtoxinA units.
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Num. of
muscles
injected

13

No injectiona

Withdrawnc
13

a

= Participants presented with minimal tremor at visit and injector made a clinical judgment against injection.
= Participants were not injected due to unattended study visit.
c
= Participant withdrew from study due to other health issues.
d
= Participant withdrew from study due to unwanted weakness.
b

The muscles selected and mean doses injected per muscle are listed in Table 3-3. The most
frequently injected muscles during the first treatment were FCR and ECR (91.7%, 22/24). All
participants were injected in the biceps for the second and third treatments.

Table 3-3. Mean injected dosage per arm muscle treated at each treatment time-point.
Week 0 (First Injection)

Muscles Injected

Mean ± SD

Num. of
Patients
(n = 24)

Week 16 (Second Injection)
Num. of
Patients
(n = 22)

Mean ± SD

Week 32 (Third Injection)

Mean ± SD

Num. of
Patients
(n = 18)

Flexor carpi
radialis (FCR)

13.9 ± 4.9

22

14.5 ± 5.4

20

12.0 ± 5.6

15

Flexor carpi
ulnaris (FCU)

12.4 ± 3.0

21

14.5 ± 5.8

20

12.3 ± 5.3

15

Brachioradialis

20.0 ± 0.0

2

27.5 ± 3.5

2

20.0 ± 0.0

1

Extensor carpi
radialis longus
(ECR)

15.7 ±5.4

22

16.5 ± 5.6

20

14.7 ± 6.7

15

Extensor carpi
ulnaris (ECU)

16.2 ± 5.5

21

16.75 ± 5.9

20

15.7 ± 6.8

15

Pronator teres
(PT)

15.3 ± 5.6

19

16.0 ± 5.8

21

15.3 ± 6.5

17

Pronator
quadratus (PQ)

15.3 ± 5.6

19

16.0 ± 5.8

21

15.3 ± 6.5

17

Supinator

15.3 ± 5.7

17

18.2 ± 6.7

19

15.3 ± 6.7

16

Biceps brachii

28.6 ± 8.4

21

30.9 ± 8.5

22

30.3 ± 9.6

18

Triceps

28.7 ± 6.1

15

29.4 ± 7.8

18

30.6 ± 9.1

16

Pectoralis major

25.4 ± 6.3

13

25.7 ± 7.3

15

29.6 ± 10.7

13
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Teres major

24.6 ± 7.5

12

25.0 ± 8.3

14

29.6 ± 11.4

12

Deltoid

28.0 ± 7.6

5

22.5 ± 5.2

6

30.0 ± 6.1

5

Supraspinatus

26.0 ± 9.6

5

21.7 ± 6.1

6

30.0 ± 8.4

6

Infraspinatus

0.0 ± 0.0

0

0.0

0

50 ± 0.0

1

All the dosages are in units of incobotulinumtoxinA. The mean values represent the average dose administered
over the number of participants injected in the particular muscle. SD values represent standard deviation of
population.

3.3.3. Clinical and Kinematic Efficacy Results
Over the 38-week period comprising of three injection cycles, severity of action tremor
(UPDRS item 21) was statistically significantly reduced [χ2(2)=17.836,p<0.0005] from
2.6±0.5 at week 0 to 1.7±0.9 at week 16 (p<0.0005) and to 1.6±1.1 at week 32 (p=0.001).
Tremor severity in the untreated limb like rest tremor (UPDRS item 20) did not significantly
change during study course.

Figure 3-3a illustrates the significant decline in FTM part A score assessing tremor severity
during rest, posture, and action positions. Compared to week 0, means for FTM part A score
for rest tremor did not meet normal distribution, thus Friedman’s test was utilized. Rest
tremor was statistically significantly reduced during the BoNT-A treatment course,
[χ2(5)=13.809,p=0.017]. Post hoc analysis revealed statistically significant reductions
[χ2(5)=37.568,p <0.0005] in postural tremor at baseline (median:2.0) to week 6
(median:1.0;p=0.015), week 16 (median:1.0;p=0.003), week 22 (median:1.0;p=0.007), week
32 (median:1.0;p<0.0005) and to week 38 (median:1.0;p<0.0005). Action tremor, by post
hoc analysis [χ2(5)=21.348,p=0.001], demonstrated significantly decreased changes in
tremor from baseline (median:2.0) to week 38 (median:0.0;p=0.002).

Total FTM part B sub-categorical scores rating the ability to write
[F(5,95)=2.286,p=0.049,partial η2=0.107] and to pour liquids with both upper limbs was
statistically significantly reduced [F(5,95)=5.867,p <0.0005,partial η2=0.236] by a mean
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difference of 4.40±1.19 FTM points at week 22 (p=0.23), 4.45±1.25 at week 32 (p=0.31),
and by 5.70±1.35 FTM points at week 38 (p=0.007) when compared to week 0 (Figure 3-3b).
Total FTM part C score, rating functional ability in eight categories, was significantly
reduced [F(5,95)=11.584,p <0.0005,partial η2=0.379] at all time-points with a final total
FTM part C sub-score of 9.5 ±6.3 (p<0.0005), plotted in Figure 3-3b. Post hoc analysis
revealed a decrease in functional disability caused by tremor by a mean difference in FTM
part C sub-score of 5.25±0.943 at week 6 (p<0.0005), 3.95±0.82 at week 16 (p=0.002),
5.65±0.92 at week 22 (p<0.0005), 4.25±0.96 at week 32 (p=0.004), and 6.05±1.12 at week
38 (p<0.0005). The most disabling tasks at week 0 were drinking (2.8±0.8 FTM score) and
working (2.5±1.0 FTM score). Across all participants, drinking ability was significantly
improved by a mean difference of 0.95±0.29 at week 6 (p=0.05) and by 0.95±0.21 at week
38 (p=0.004). Working performance was statistically significantly improved at all timepoints [F(5,90)=4.751,p =0.001,partial η2=0.209]. Other FTM categories such as eating,
dressing and hygienic activities significantly improved and functional disability due to
tremor did not return to baseline severity. ET participants reported elevated quality of life,
measured by QUEST (Figure 3-3c). Mean total QUEST score was significantly reduced
[F(5,95)=4.620,p=0.001,partial η2=0.196]; post hoc analysis showed quality of life
significantly improved at the time of and following the third treatment, by a mean difference
of 9.45±2.69 at week 32 (p=0.035) and by 10.50±2.91 at week 38 (p=0.028), when compared
to baseline.

Kinematic tremor assessments allowed objective monitoring of tremor severity before and
after incobotulinumtoxinA therapy. Figure 3-3d displays angular tremor RMS amplitude and
acceleration captured at the finger and hand values analyzed together over two postural
(”posture-1” and “posture-2”) and two weight-bearing (”load-1” and “load-2”) tasks. Though
joint angles and acceleration, which is quantified by the sum of acceleration in the X-, Y- and
Z- axis, indicate different characteristics, they both represent tremor severity. Mean wrist
RMS amplitude was significantly reduced [F(2.297,85)=7.594,p=0.001,partial η2=0.309] by
mean difference of 0.39±0.10 at week 6 (p=0.014), by 0.43±0.12 at week 22 (p=0.027) and
by 0.41±0.09 at week 32 (p=0.005). Mean elbow tremor amplitude during both weight63

bearing tasks (load-1: χ2(5) = 13.587, p =0.018; load-2: χ2(5) = 11.714, p =0.039] produced
statistically significantly different changes over treatment course. Mean elbow tremor during
posture-2 (arms outstretched with palms facing inwards) [χ2(5)=14.413,p =0.013]
demonstrated a significant decrease in tremor by a mean difference of 2.278±0.62 at week 32
(p=0.004). Hand tremor acceleration significantly decreased [χ2(5)=27.937,p<0.0005] across
all time-points except at week 16, correlating to the change in wrist tremor amplitude (Figure
3-3d). Weight-bearing tasks produced the largest acceleration at the finger and hand.

Analyzing tremor per task (Figure 3-3e), load-2 produced the largest mean tremor amplitude
of 0.9±0.7 RMS degrees (median: 0.81) in the wrist at week 0 which was significantly
reduced [χ2(5)=20.667,p=0.001] to 0.5±0.6 degrees at week 6 (median:0.34;p<0.0005).
Similar reduction in wrist tremor was observed during posture-1 [χ2(5)=18.921,p=0.002],
posture-2 [χ2(5)=22.636,p <0.0005], and load-1 [χ2(5)=22.635,p <0.0005] tasks for all timepoints excluding week 38 for posture-1 and for load-1.

Significant change in maximal grip strength [F(2.730, 49.132)=11.155,p <0.0005,partial
η2=0.383] coincided with peak effect of toxin but did not affect arm functionality or quality
of life (Figure 4-5f). Maximal grip strength was significantly reduced from 24.7±10.7 kg at
week 0 to 18.5±12.4 kg at week 6 (mean difference of 6.51±1.54; p=0.007). A significant
reduction in maximal grip strength however did not indicate any impact on arm function,
demonstrated on a Likert scale for self-reported perceived muscle weakness (Figure 3-3f, red
line). At week 6, 12 participants (50%) reported a Likert score of 0, no weakness, two
participants (8.3%) reported a 1, mild weakness with no loss in function, seven participants
(29.1%) reported a 2, moderate weakness in injected muscles, and three participants (12.5%)
reported a 3 indicating marked arm weakness. Following third treatment at week 38, eight
participants (40%) experienced no weakness; eight and four participants reported a score of 1
and 2, respectively.
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Figure 3-3. IncobotulinumtoxinA treatments significantly reduced severity of tremor
and provided functional benefit for fine and gross motor tasks with mild muscle
weakness in treated muscles.
(A) Tremor severity, FTM part A sub-category score (max: /4 per task), significantly
decreased. (B) Handwriting, spiral and line writing tasks showed significant improvement,
signified by FTM part B summed score, and functional disability, FTM part C summed score
(max: /4 per category, 8 categories in total), was significantly reduced. (C) Quality of life,
measured by QUEST tallied 30-items (max: /4 per item), significantly increased. (D) Angular
RMS tremor amplitude (primary y-axis) and hand and finger acceleration values (secondary
y-axis) at each arm joint was averaged per time-point. Significant reductions in wrist and
shoulder tremor amplitudes resembled change in hand and finger acceleration values. (E)
Angular wrist tremor RMS amplitude for each scripted-task was significantly reduced. (F)
Maximal grip strength (blue) was significantly reduced, but did not impair function, and
perceived muscle weakness (red) yielded no significant change at injection visits. All plotted
values are means for all participants per each time-point. Asterisks represented statistical
significant change (p<0.05) compared to baseline. Error bars represent standard deviation of
population.

3.4. Discussion
This is the first study that uses whole limb kinematics to segment complex movements at
multiple joints comprising of tremor in order to determine if efficacy and tolerability of
incobotulinumtoxinA (BoNT-A) as a focal therapy is achievable. Kinematics provides an
objective readout of the angular motion of tremor acting at each joint during a variety of
tasks thereby providing the composition of tremor. This composition is unique for every
patient and thus the selection of contributing joints, muscles that move the joint in the
affected degrees of freedom and the dosing of these muscles can be individualized. An
objective, repeatable platform of measuring the biomechanical properties of the tremor
means that the same measurements can be carried out at any time point after the injection to
determine the effect of injection. Such tools can record motion at multiple joints
simultaneously, for an extended period of time, that can be averaged and thereby give a
comprehensive dynamic view of the tremor. Visual assessment does not meet any of these
criteria.
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In the process of injection determination, the injector initially chooses a total dose based on
the kinematic readout thus permitting dose allocation to muscles selected kinematically. Such
targeting immediately individualizes the injections to the kinematic signature of the patient.
Subsequent optimization by measuring the effect of the injection at subsequent visits is also
possible, as demonstrated in this study. This longitudinal study demonstrates for the first time
sustained relief of tremor and functional interference caused by ET by employing kinematics
in personalizing injection parameters with a low incidence of weakness. By using such
technology, a standardized method to assess tremor has been established and these results can
be used to improve focal therapy thereby paving a way to offer clinicians and patients with
alternate options for treating tremor.

ET patients who seek treatment suffer from functionally disabling tremor which restricts
performance of every-day activities.1 As 30% of patients do not respond to standard
pharmacological medication and yet another 30% who start drug therapy will discontinue
treatment due to side effects, an effective tremor therapy is needed.4,6 Thalamotomy and
thalamic stimulation is often age restricted, has strict guidelines including cognitive status,
and is not accessible to many due to the requirements for a specialized centre. In addition,
significant irreversible complications including dysarthria and gait difficulties can occur. As
such surgical therapies are often restricted to a small group of severally disabled patients,
which highlights the need for a targeted treatment such as BoNT-A injections. Prior studies
have utilized BoNT–A injections as focal treatment, though significant finger and wrist
muscle weakness has curtailed its use, despite its promising clinical benefit.10,11,22–24 To
improve BoNT–A efficacy and to reduce incidence of unwanted effects, this study addressed
several major prior study limitations. These limitations include inability to determine the
joints and their dynamics for the involved tremor, fixed and/or randomized dosing, subjective
and/or fixed number of muscles selected, lack of individualization of injections to the
participant’s tremor, and number of injection cycles.
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Accurate measurement of movement in multiple degrees of freedom at each upper limb joint
is the first unmet need that has been addressed by our technology. Selection of tremulous
muscles has previously been established by using a fixed method, injecting only flexor and
extensor wrist muscles,10,22,23 by using single joint surface EMG electrodes,8 or by combining
accelerometry and surface EMG.11 The assumption here is that the tremor at the wrist is
mainly unidirectional (F/E) and contributions from the elbow and shoulder joints are not
measurable. Hence, accurate localization or segmentation of tremor at wrist, elbow and
shoulder joints was not performed. This creates significant segmentation errors as a
significant portion of the tremor originates from movements other than wrist F/E and indeed
from proximal joints. Unlike accelerometers which provide tremor amplitude data for the
entire arm, the sensors employed in this study allowed independent characterization of
motion at the wrist, elbow, and shoulder joints, which is a difficult task by visual assessment
or accelerometric and surface EMG measurements alone.13,15,16 Based upon the composition
of movement dynamics at multiple joints and in multiple directions at each joint, the
contributing muscles were selected (Figure 3-2a). Injection patterns are thus tailored to each
participant’s kinematics (Figure 3-2b) instead of using visual methods or by standard set of
injections, utilized in prior studies.

Fixed and randomized dosing, preselected muscles that may not actually be involved, while
allowing a standardized approach to injection, fails to take into account an important aspect
of significant individual variation in tremor. Applying objective kinematic technology to
every patient uniquely provides a “read-out” of the patient’s own tremor. This approach can
thus reduce potential unwarranted weakness and indeed improve efficacy as the correct joints
and muscles are targeted. Dose-dependent limb weakness limited functional efficacy of
BoNT–A as shown in several earlier studies that utilized a fixed- or randomized-dosing
method.10,22-24 In addition, Brin MF and colleagues did display reduced postural tremor
severity by using accelerometers, but could not show functional benefit following a BoNT–A
treatment.10 Hence, in this study, individualizing injection patterns optimized tremor therapy
by characterizing the joints involved and by quantifying the angular displacement of tremor
in each degree of freedom, an analysis only capable by the use of kinematics. Based upon the
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clinician’s judgment, muscles predominantly contributing to the total tremor were selected,
though these muscles may vary somewhat depending upon the personal choices of the
clinician.

An important unmet need with clinical assessments is the ability to change the dosing at a
subsequent visit. Since visual assessment does not provide an objective record of the
patient’s prior limb motion, there is no objective way to compare the limb motion at
subsequent visits. Kinematics is quantitative and repeatable, thereby providing a simple way
for the clinician to determine the pattern of the original joint involvement and then continue
optimization at any visit that is desired after that. In this study, we were able to achieve this
optimization. Changes in BoNT-A dosages between treatments were calculated to optimize
response by comparing the severity of tremor pre- and post-injection solely using kinematics,
a personalized, targeted therapy unachievable by oral medications.

By using kinematic methodology, statistical significant functional benefit, particularly for
eating, drinking and working performance reported in the FTM scale, was achieved six
weeks following the first treatment and throughout the study course along with reductions in
tremor severity during rest, postural, and action tasks (Figure 3-3a-e). These benefits
generated a statistical significant improvement in quality of life scores, ranging across
physical, psychosocial, communication, hobbies/leisure, and work/finance activities, at week
32 and 38 (Figure 3-3c), which has not been achieved in any of the prior BoNT-A studies for
upper limb essential tremor.1 Along with these physical and functional benefits, maximal grip
strength was statistically significantly reduced at study visits, but functional strength was
only minimally affected as demonstrated by the Likert perceived weakness scale (Figure 33f). A mild decrease in maximal grip strength was attributed to a modest toxin effect to the
neighboring finger flexors by transfascial diffusion and/or to other synergistic muscles.
Finger muscles were not directly treated because the kinematic tremor analysis did not
include finger sensors. Thus, benefits of using kinematically-guided injections indicated
relief of tremor, functional benefit and demonstrated less muscle weakness compared to prior
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studies. These results indicate that incobotulinumtoxinA injection parameters determined
using kinematics can effectively and tolerably reduce upper limb tremor, while keeping
weakness related side-effects low. A clinician familiar with the anatomy and who is
knowledgeable about BoNT-A dosages typically given to these muscles for other indications,
such as spasticity, now has the ability to confidently treat tremor using kinematics as
guidance. By accurately pinpointing joint dynamics in ET, individualization and optimization
of tremor treatment is a possibility.

3.4.1. Study Limitations
Non-blinded injections and no treatment comparator were limitations of this study. However,
in this longitudinal study, outcomes were kinematically and objectively determined with
serial injections and hence a persistent placebo response is unlikely. Blinded studies with
BoNT–A are difficult as weakness is obvious and easily perceived by participants and
investigators. Similarly, cross-over designs are challenging as it is impossible to determine a
true return to baseline in injected participants for accurate cross-over time. Final muscle
injection pattern was determined by the treating physician and may vary. However, this
allows even better individualization and flexibility. The study did not compare visually
guided versus kinematically guided injections as the lack of tolerability and efficacy with
injections based on visual assessments has already been demonstrated in the literature.
Sample size was similar to previous literature.10,23 As tremor is variable throughout a given
day and participants were assessed while on their anti-tremor medications, severity
fluctuations could have introduced error during each visit. Thus, participants were assessed
around the same time of day.

It is also important to note that only one of the arms was injected to allow participants’
functionality of at least one limb in case of unwarranted side effects of weakness. Although
the most affected arm for functionality was treated, it is possible that even further
improvements in quality of life can be achieved if both arms had been injected from the start.
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3.5. Conclusion
This study clearly demonstrates that utilizing an objective, kinematically-based assessment of
upper limb tremor provides a clinician with critical guidance for selecting which joints are
affected and in what proportion. This allows for targeted, individualized muscle selection to
significantly improve efficacy of consecutive incobotulinumtoxinA injections for tremor. For
the first time, incobotulinumtoxinA injections have effectively treated essential tremor and
enhanced the quality of life of patients suffering with essential tremor by improving
functional ability of their whole arm.
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4. Effective management of upper limb parkinsonian tremor by botulinum toxin type
A injections using sensor-based biomechanical patterns4
4.1. Introduction
Tremor is a cardinal sign of Parkinson disease (PD) and is one of the most challenging
symptoms to treat. In PD patients, tremor is predominantly present at rest as compared to
posture or task-specific movement.1-3 Tremor causes difficulty in performing daily activities
and significantly affects quality of life.4 Levodopa remains the most potent drug for
managing PD symptoms yet it results in significant complications such as “wearing off”
motor fluctuations and dyskinesia and thus its use as a starting therapy for PD tremor is
discouraged.5-7 Dopamine agonists and anticholinergic medications can be used
concomitantly with levodopa to treat tremor but may be accompanied by neuropsychiatric
and cognitive side effects.8,9 Deep brain stimulation (DBS) is an effective treatment for
treating recalcitrant PD tremor though this is an invasive procedure and optimization of
programming parameters still remain unclear. Therefore, physicians and patients are reluctant
to use conventional pharmacotherapy as the first line of defense for tremor. Alternative
methods for treating tremor must be considered, as an effective therapy is an enormous
unmet need in tremor dominant PD patients.

Visual assessment of upper limb tremor is restricted by the difficultly to separate multi-joint,
whole-arm movements. Characteristics of tremor such as severity at the fingers, wrist, elbow,
and shoulder vary per patient and voluntary tasks alter upper limb biomechanics.2 Wrist
tremor is complicated by the wrist’s ability to simultaneously flex-extend, pronate-supinate,
and deviate from side to side, commonly seen during rest and described as a “pill-rolling”
action in the hand.10 Elbow and shoulder tremors are challenging to segment due to the size
of these joints and consequently their small amplitude movements make significant impact at
the most distal part of the arm. Similar to the wrist, the biomechanics of the shoulder
simultaneously moves in two directions, abduction-adduction and flexion-extension.11 Thus,

4
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patterns. Tremor Other Hyperkinet Mov. 2015; 5. doi: 10.7916/D8BP0270. *co-authors).
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understanding tremor biomechanics is crucial for targeting specific muscle groups for
effective symptomatic treatment by incobotulinumtoxinA (BoNT-A) injections.

Treating upper limb tremor with BoNT-A intramuscular injection has not been widely
adopted in clinical practice in PD tremor, despite some success in reducing tremor severity
and improving functional rating scores.12,13 Limited improvements were attributed to mainly
muscle weakness. Significant muscle weakness from rigid protocols using a fixed dose and
pre-determined group of muscles to inject, regardless of the patient’s tremor characteristics,
may contribute to limb weakness and subsequent loss of function.14,15 Even with techniques
such as electromyography- or ultrasound-guided needle injections that minimize toxin
spread, muscle weakness can still occur.16 Another factor contributing to the low efficacy
reported in prior studies may have been due to only having one or two treatment cycles with
short follow-up visits.17,18 The lack of objective tremor assessments to monitor the dynamic
movements at each joint may also be a factor hindering optimization capability and
therapeutic outcome. Ultimately the selection of appropriate muscles to inject at each joint
remains the most important issue which kinematics can solve by simplifying assessment of
tremor and guide therapy.

Kinematic technology has been used to study the biomechanics of motion in many scenarios
including gait and whole body characteristics.19,20 The use of such multi-sensor motion
recordings for tremor feature extraction is well understood.21 Successful focal tremor therapy
has recently been performed by using the biomechanics of tremor at each of the three arm
joints for standardizing selection of injection parameters.21 Thus, efficacious use of
incobotulinumtoxinA, as a focal treatment, requires appropriately determined injection sites
and dosage per muscle.22 To determine these parameters, a clinician can use kinematic
characterization of a patient’s upper limb tremor to select muscles known to contribute to the
joint movement. This was investigated in the longest-to-date open label study involving 28
PD participants who received three incobotulinumtoxinA injection treatments based upon
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kinematically guided muscle selection criteria for upper limb PD tremor every 16 weeks over
a 38-week duration.

4.2. Methods
4.2.1. Study Criteria and Timeline
This open label, single-centre, single-injector study (Health Canada CTA# 178589) recruited
a convenience sampling of 28 PD participants from the London Movement Disorders Centre
in London, Ontario who provided written consent and attended six study visits at weeks 0, 6,
16, 22, 32, and 38 and were treated with incobotulinumtoxinA (Xeomin®) at weeks 0, 16,
and 32. Treatment-naïve participants were maintained on monotherapy of
incobotulinumtoxinA injections for their PD throughout the study while participants on
treatment did not change their medications throughout the study. Participants on stable PD
medication, with inadequate tremor relief, were assessed in the “ON” state during, and at
approximately the same time of the day at all study visits. Each study visit involved
completion of clinical scales and kinematic tremor measurements. IncobotulinumtoxinA (0.5
mL of saline per 100 unit vial) was injected into the tremor dominant limb under
electromyographic (EMG) guidance using a Clavis® portable EMG device (1” long 30 g
injectable EMG needle).

4.2.2. Study Inclusion/Exclusion Criteria
The Western University Health Sciences Research Ethics Board approved this clinical phase
IIb pilot study protocol (REB#18445). All ongoing and related trials for this
drug/intervention are registered (ClinicalTrials.gov Identifier: NCT02427646). The study’s
progress is outlined in the CONSORT flowchart displayed in Figure 4-1. The
inclusion/exclusion criteria outlined in Chapter 2, section 2.2.2.2 were used for this study.
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Figure 4-1. CONSORT Flow Diagram Displaying the Progress of the Study Design.
Progress through the various stages of a trial including flow of participants, number of
participants and reasoning of withdrawals and the number of participants included for
analysis.

4.2.3. Clinical Scale Assessment
The same standardized questionnaires and clinical scales used in Chapter 3 were used for the
data discussed in this current chapter (see section 3.2.5).

4.2.4. Kinematic Assessment
Kinematic measures of tremor were conducted while participants were in their “ON” state
rather than their “OFF” state to reduce any overestimation of tremor severity. As participants
were already stable on their oral medications, kinematic assessment was deemed to be best
determined after taking into account the optimal medication response which was in the “ON”
state. The sensor calibration tasks and a series of two rest and two postural scripted tasks,
previously described in Chapter 2 (Figure 2-1a-d), were performed by each participant while
seated with motion sensor devices placed over each arm joint, as pictured in Figure 2-2 in
Chapter 2. The same custom-written Matlab® code, described in Chapter 2, was used to
extract angular position and angular tremor amplitude in RMS degrees from each DOF per
arm joint.

4.2.5. Injection Determination
This study followed the same protocol described in Chapter 3, section 3.2.4.

4.2.6. Statistical Analyses
The means and standard deviations of both kinematic and clinical data were analyzed using
SPSS® statistics version 21 by performing one-way repeated measures ANOVA using
confidence intervals of 95% (ɑ=0.05) with post hoc Bonferroni corrections for multiple
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comparisons performed across all time-points. Clinical scales were represented by mean and
dispersion of the data from the mean, standard deviations of the population, for each timepoint. The mean angular RMS tremor amplitude for all three trials per task at each time-point
was log-transformed as tremor amplitudes generated positively skewed distributions. Tremor
accelerometry values captured in the X-axis, Y-axis and Z-axis for each task were averaged
per participant at each time-point. Missing of random value analysis was conducted for all
independent variables to ensure incomplete data sets were missing completely at random and
multiple imputation method was not utilized for this dataset. The means from each clinical
rating scale and from the kinematic tremor analyses that met criteria were tested for
normality using the Shaprio-Wilk test and z-score for skewness and kurtosis. The means that
met parametric analysis criteria underwent parametric ANOVA tests to determine the
presence of significant changes between time-points when compared to week 0. Means
which did not meet parametric test criteria were tested using the Friedman’s test. Partial etasquared (partial η2) was reported as an estimate of the population effect size.

4.3. Results
4.3.1. Participant Demographics
Demographics and baseline clinical scores of the 28 PD study participants are shown in
Table 4-1. Following the first treatment at week 16, 11% of participants (3/28) withdrew due
to experiencing both inadequate functional benefit and bothersome muscle weakness.
Following the second treatment at week 32 and focusing on the remaining 89% of
participants (25/28), one participant withdrew due to unwanted weakness, and two
participants failed to maintain inclusion criteria such as lack of study attendance and
medication change. Of the remaining participants (22/28), four did not continue past week 32
due to: unwanted weakness (9%, 2/22), failed study attendance (4%, 1/22), and change in
other PD symptoms (4%, 1/22). Thus, only a total of six PD participants (21%) experienced
unwanted weakness warranting study withdrawal following three treatments. However, this
implies that 79% of patients did not have enough weakness to discontinue participation in the
study.
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Table 4-1. PD participant demographics and baseline UPDRS scores.
Baseline Scores
Patient
ID

Gender

Age

Years
with
tremo
r

Injected Dominan
limb
t limb

Weight
(lbs)

Item 20
Nontreated
arm (/4)

Item 20
Treated
arm (/4)

Item 21
Nontreated
arm (/4)

Item 21
Treated
arm (/4)

1

F

71

11

L

R

170

0

2

1

2

2

M

35

7

R

R

350

0

2

0

3

3

M

62

7

R

R

175

0

3

0

0

4

M

79

7

R

R

165

2

3.5

1

1

5

M

53

10

L

R

-

2

3

1

2.5

6

M

43

5

L

R

-

1

2

1

2

7

M

60

7

R

R

225

1

3

1

2.5

8

M

79

14

R

R

-

4

4

2

2

9

M

59

11

R

R

275

2

2

1

1

10

F

77

9

L

R

185

1

3

1

2

11

M

62

5

R

R

203

2

3

0

0

12

M

66

7

R

R

185

0

2.5

1

1

13

M

76

6

R

R

152

1

2

0

1

14

F

54

6

R

R

140

0

2

1

0

15

F

50

-

R

R

-

0

3

0

2

16

F

75

-

R

R

-

0

3

2

2

17

F

62

8

L

R

152

2

3.5

1

2.5

18

F

47

14

R

R

193

1

2

1

2

19

F

71

-

R

R

-

0

2.5

1

2

20

M

80

9

R

R

150

0

3.5

0

0

21

M

59

7

L

R

170

0

3

0

2

79

22

M

69

6

R

R

234

0

3.5

0

2.5

23

F

70

6

R

R

165

2

2

2.5

2.5

24

M

68

14

R

R

160

3

3

1

1

25

M

70

7

R

R

165

0

3.5

0

3.5

26

M

69

-

L

R

215

0

2

0

1

27

F

80

5

R

R

150

1

2.5

1

1

28

F

66

-

L

R

168

1

2.5

0

1

65.5

7.5

188.2

0.9

2.7

0.7

1.6

8L

1L
± 47.5

± 1.0

± 0.6

± 0.7

± 0.9

Mean
7F
± SD

± 11.5

± 3.1

Weight data was collected as a correlational measure towards each individual’s total injected joint dose and is
reserved for reference for future pilot studies. F, Female; L, Left; M, Male; PD, Parkinson’s Disease; R, Right;
SD, Standard Deviation; UPDRS, Unified Parkinson’s Disease Rating Scale.

4.3.2. Selecting Kinematically-Based IncobotulinumtoxinA Injection
Parameters
Kinematics was utilized to quantify two key characteristics of tremor for optimizing
incobotulinumtoxinA therapy: severity of total tremor (angular RMS amplitude) and
directional contribution of the tremor at each arm joint. Figure 4-2a displays a sample
participant’s kinematic tremor measures during each of the four tasks by plotting the total
tremor severity (plots 1) in the wrist, elbow and shoulder joints and segmenting total tremor
in the wrist and shoulder joints by directional movements of the total tremor (plots 2). The
task with the largest tremor amplitude served as a biomechanical basis for determining
BoNT-A injection parameters. The movement disorders neurologist interpreted the
kinematics by basing the total dose on total tremor severity (plots 1). This total dose was
ultimately divided amongst select muscles which generated these fundamental tremulous
movements, focusing on the distribution of the total tremor in each DOF (plots 2) at each arm
joint (Figure 4-2b). In the example in Figure 4-2a, “rest-2” task, with forearm supported,
generated the largest tremor severity at the wrist, elbow and shoulder joints. Thus, allocation
of the total dose was distributed according to the division of the total tremor, illustrated in
plot 2 for wrist and shoulder joints in Figure 4-2a.
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Figure 4-2. Sample participant kinematic data readout of tremor generated from the
wrist, elbow and shoulder joints and individualized muscle selection based on both
kinematic tremor profile and the injector’s best clinical judgement.
(A) Total tremor severity (plot 1) is displayed in angular RMS amplitude and the percent
directional contribution of tremulous movement (plot 2) by 3 DOFs in the wrist and by 2
DOFs in the shoulder joint. Error bars indicate standard deviation over three trials. (B)
Injector’s interpretation of the kinematic results showing selection of total dose allocated to
wrist, elbow and shoulder muscle groups based on tremor severity and the muscles selected
based on the amount of tremor present in each degree of freedom each arm joint moves in.
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Injection parameters were optimized solely using kinematics by comparing the change in
tremor at baseline to kinematic measures of tremor at six weeks and sixteen weeks posttreatment. A reduction in total tremor during a task at the six week follow-up visit indicated
the appropriate muscles were targeted. An increase in BoNT-A dose was required if the
tremor could have been reduced further, as quantified by kinematics at post-treatment
assessments, and no presence of side effects as perceived by participant (reported in the
Likert scale). A reduction in dose was indicated by the participant experiencing prolonged
muscle weakness in injected muscles lasting more than one month, as rated by the Likert
scale for muscle weakness, and reporting weakness as functionally bothersome.

The mean total dose per arm did not significantly change between the first and third
treatments, however the mean number of injected muscles gradually increased, shown in
Table 4-2. The total dose for the second treatment was increased for 47.6% of participants
(10/21) and was reduced for 14.2% (3/21). Of those who required an increased BoNT-A
dosing at the second treatment, at the third treatment, 10% of participants (1/10) required a
reversal of the increased BoNT-A reverting to the original parameters and 20% of
participants (2/10) required an additional increase in the total dose. One participant whose
total dose increased at the second treatment was not injected at the third treatment due to
prolonged moderate muscle weakness. The total dose was reduced for 13.3% of participants
(2/15) whose parameters were not altered during the second treatment though required a
reduced total dose at the third treatment.

Table 4-2. Total injected dosage and number of muscles injected as determined by injector
across all participants
Week 0 (First
Week 16 (Second Injection) Week 32 (Third Injection)
Injection)
Patient
ID

BoNT-A Num. of
dose (U) muscles

BoNT-A dose
(U)
82

Num. of
muscles

BoNT-A dose
(U)

Num. of
muscles

injected

injected

injected

1

100

6

No Injection*

75

2

200

7

200

7

No Injection*

3

100

6

100

6

No Injection*

4

100

8

200

8

No Injection*

5

100

8

100

8

No Injection*

6

100

6

Withdrawn#

Withdrawn#

7

200

8

No Injection*

200

8

275

8

Withdrawn#

Withdrawn#

9

260

9

390

10

125

7

No Injection**

11

140

8

175

9

No Injection***

12

100

8

170

8

100

8

13

175

8

175

8

135

8

14

95

7

95

7

95

7

15

320

11

350

11

Withdrawn#

16

200

11

Withdrawn##

17

200

11

280

9

300

8

18

200

10

200

10

200

10

19

200

6

Withdrawn#

20

265

13

300

13

300

13

21

200

8

280

12

300

13

22

200

8

100

8

100

8

23

190

11

170

11

170

11

11

83

8

8

No Injection*
125

7

Withdrawn##

Withdrawn#

24

200

8

200

8

200

11

25

300

12

300

12

300

12

26

100

7

200

9

Withdrawn##

27

130

9

200

11

200

28

100

6

80

6

Withdrawn###

Mean ±
SD

174.1 ±
66.8

8.4 ± 1.9

203.1 ± 84.4

9.1 ± 2.0

11

186.7 ± 79.5

9.5 ± 2.1

Dosing was in incobotulinumtoxinA units. * = Participant presented with minimal tremor at visit and injector
made a clinical judgment against injection. ** = Participants subjectively reported prolonged mild unwanted
weakness in non-injected muscles in treated arm, but had functional benefit. *** = Participant perceived
prolonged moderate wrist extensor weakness with limited functional benefit. # = Participant withdrew from
study due to wrist extensor weakness. ##= Participant withdrew from study due to lack of time commitment. ###
= Participant withdrew from study due to changes in PD symptoms and met exclusion criteria.

Muscles selected and mean administered dose per muscle are summarized in Table 4-3. For
the first treatment, all participants were injected in FCU and ECU. The most frequently
injected muscles during the second injection cycle (20/21) were ECU, PT and PQ and FCR,
ECR, PT, PQ and supinator during the third treatment (14/15).

Table 4- 3: Mean injection dosage by arm muscle treated at each treatment time-point.
First injection (Week 0) Second injection (Week 16) Third injection (Week 32)

Muscles injected

Mean ± SD

Num. of
patients

Mean ± SD

(n = 28)

Num. of
patients

Mean ± SD

(n = 21)

Num. of
patients
(n = 15)

Flexor carpi
radialis (FCR)

16.3 ± 7.0

24

15.6 ± 5.7

17

13.6 ± 5.8

14

Flexor carpi
ulnaris (FCU)

16.8 ± 6.7

28

16.1 ± 5.8

19

14.2 ± 5.5

13

Brachioradialis

20.0 ± 0.0

1

20.0 ± 0.0

1

20.0 ± 0.0

1

Extensor carpi

18.5 ± 8.2

24

17.5 ± 5.8

18

16.1 ± 5.4

14

84

radialis longus
(ECR)
Extensor carpi
ulnaris (ECU)

18.6 ± 7.9

28

17.5 ± 5.8

20

16.5 ± 5.3

13

Pronator teres
(PT)

17.4 ± 5.1

25

17.8 ± 4.9

20

15.7 ± 4.2

14

Pronator
quadratus (PQ)

16.0 ± 4.9

25

17.3 ± 5.1

20

15.4 ± 4.8

14

Supinator

17.3 ± 4.5

22

18.1 ± 4.8

18

16.8 ± 7.0

14

Biceps brachii

33.9 ± 10.3

23

36.3 ± 10.4

19

30.4 ± 9.7

12

Triceps

29.5 ± 10.1

10

32.7 ± 9.6

11

28.1 ± 9.3

8

Pectoralis major

33.3 ± 8.8

9

34.5 ± 13.0

11

28.1 ± 9.3

6

Teres major

25.8 ± 6.7

6

30.0 ± 12.2

8

29.2 ± 10.6

8

Deltoid

30.0 ± 9.4

4

32.0 ± 9.3

5

30.0 ± 5.5

5

Supraspinatus

28.0 ± 2.4

5

30.0 ± 5.5

5

27.5 ± 2.5

4

All the dosages are in units of incobotulinumtoxinA. The mean values represent the average dose
administered over the number of participants injected in the particular muscle. SD value represents standard
deviation of population.
4.3.3. Clinical and Kinematic Efficacy Results
Severity of rest tremor (UPDRS item 20) in treated arm was significantly reduced
[F(2,40)=8.378,p=0.001, partial η2=0.295] from 2.7±0.6 at week 0 to 2.0±0.8 at week 16
[p=0.006] and to 2.1±0.7 at week 32 [p=0.014]. Action tremor (UPDRS item 21) was
reduced in the treated arm from 1.6±0.9 at week 0 to 0.9±1.0 [p=0.09] at week 16 and to
1.0±0.8 at week 32, though this was not statistically significant [F(2,40)=2.832,p=0.071,
partial η2=0.124] (Figure 5a).

FTM part A score, indicating tremor severity, significantly reduced [F(5,65)=2.043,p=0.024,
partial η2=0.136] at week 6, compared to week 0 (Figure 5b). Though mean total FTM part B
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score assessing handwriting and pouring function did not produce a significant reduction
[F(5,60)=1.820,p=0.123, partial η2=0.132]. 25% of participants (7/28) indicated their arm
tremor was the root source of functional disability, as opposed to other PD symptoms
interfering with ADLs including eating, drinking, and working tasks (Figure 5b). For these
participants, eating (solid food) FTM subcategory score was significantly reduced [F(5,30)
=2.558,p=0.048, partial η2=0.299] and produced strong evidence of functional improvement
from 2.3±0.4 at week 0 to 1.3±0.7 [p=0.056] at week 38, though this was not significant as
demonstrated by Bonferroni pairwise comparisons.

Kinematics displayed a significant reduction in tremor severity at each arm joint during rest
and postural states over the treatment course (Figure 5c). By analyzing tremor severity over
all of the four tasks, a statistically significant reduction in RMS tremor amplitude
[F(5,65)=7.096,p<0.0005, partial η2=0.353], captured by motion-sensor devices, was
displayed in the wrist alone (Figure 3c); this was observed following the initial treatment at
week 6 [p=0.004], at week 32 [p=0.032], and following the third treatment at week 38
[p=0.003]. Though tremor acceleration, averaged X-, Y- and Z-axis values, and joint
amplitudes both measure tremor severity, they indicate different characteristics. Mean finger
acceleration over the four tasks resembled a similar change in tremor severity to wrist joint
angles and significantly decreased [F(5,65)=9.057,p<0.0005,partial η2=0.411] following first
injection at week 6 [p=0.001], following the second treatment at week 22 [p=0.028], at week
32 [p=0.03] and following the third treatment at week 38 [p=0.003] (Figure 3c). Likewise,
tremor accelerometry captured at the hand demonstrated significant reduction
[F(5,65)=7.786,p<0.0005,partial η2=0.375] at week 6 [p=0.003], week 22 [p=0.006], week
32 [p=0.003], and at week 38 [p=0.003] (Figure 5c). The severity of elbow tremor amplitude
significantly decreased [F(5,65)=3.962,p=0.003, partial η2=0.234] from 0.46±1.240 at week
0 to 0.08±0.272 RMS at week 6 (p=0.029) (Figure 5c). Shoulder RMS tremor amplitude did
not significantly change over study course.
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Analyzing tremor severity per task, mean wrist RMS amplitude during “rest-1, supinated
hand laying on participant’s lap, did not significantly change [F(5,65)=1.422,p=0.228, partial
η2=0.099] (Figure 5d). Though RMS tremor measured during “rest-2”, forearm partly
pronated while supported, was significantly reduced ([F(5, 65) = 3.740, p=0.005, partial
η2=0.223] from 1.2±1.2 at baseline to 0.7±1.1 at week 6 [p=0.045] and to 0.6±0.7 at week 32
[p=0.004]. Mean wrist RMS amplitude during “posture-1” was significantly reduced
[F(5,65)=7.410,p<0.0005, partial η2=0.363] at week 6 [p=0.003], week 22 [p=0.026], and at
week 32 [p=0.05]. Wrist tremor amplitude captured during “posture-2” was significantly
reduced [F(5,65)=4.205, p=0.002, partial η2=0.244] at week 6 [p=0.013]. Finger acceleration
significantly decreased [F(5,65)=8.538,p<0.0005, partial η2=0.396] during “posture-1” at
week 6 [p=0.005], week 22 [p=0.009], week 32 [p=0.23] and at week 38 [p=0.027] (Figure
5e). Likewise, finger acceleration during “posture-2” decreased
[F(3.025,40.112)=4.589,p=0.007, partial η2=0.261] at week 6 [p=0.025]. During “rest-2”,
finger tremor acceleration significantly reduced [F(5,65)=3.876,p=0.004, partial η2=0.230] at
week 6 [p=0.023] and at week 38 [p=0.005].
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Figure 4-3. IncobotulinumtoxinA treatments significantly reduced tremor severity and
improved arm function in the treated arm of PD participants reported qualitatively and
quantitatively.
(A) UPDRS item 20 and 21 mean scores (max: 4/arm) for rest and action tremor,
respectively. (B) FTM part A score (max: 12/arm), sum tremor severity during rest, posture
and action tasks, significantly decreased. FTM part C score (max: 4/category), functional
disability, was significantly reduced for eating tasks (N=7). (C) Angular RMS tremor
amplitude (primary y-axis) and hand and finger accelerometer values (secondary y-axis) for
each arm joint were averaged over 2 rest and 2 postural tasks per time-point. Significant
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reductions in wrist amplitude and finger accelerometry were observed. (D) Angular wrist
tremor RMS amplitude displayed for each rest and postural task showed significant
reduction. (E) Maximal grip strength (blue) and perceived muscle weakness (red) yielded
significant change at week 22. Asterisks represent statistically significant change (p<0.05)
compared to baseline. Error bars represent standard deviation of population. Sample size (N)
shown in brackets displayed on the x-axis.

4.3.4. Side Effects
Maximal grip strength was significantly reduced [F(5,60)=6.350,p<0.0005, partial η2=0.346]
from 29.2±9.5 kg at week 0 to 21.8±9.4 kg at week 22 [p=0.05] and returned to baseline
strength of 24.4±8.8 kg at week 32 (Figure 5f). Significant change in maximal grip strength
was perceived as mild weakness in injected muscles by participants, a mean rating of 1 out of
4 on the Likert scale of muscle weakness. Though significant change in perceived weakness
occurred following the second treatment, an increase from 0.2±0.4 at week 0 to 1.1±0.6 at
week 22 [p=0.03]. This coincided with the peak effect of incobotulinumtoxinA. Mean
maximal grip strength of the untreated arm was 32.3±11.1 kg at week 0 and remained
unchanged over the treatment course. Severity and frequency of perceived weakness reported
in the Likert scale for each time-point is summarized below in Table 4.

Table 4-4. Number of participants who perceived weakness using a Likert scale over the
treatment course
Number of participants per
Likert score
Time

0

1

2

3

4

Week 0 (n = 18)

15

3

-

-

-

Week 6 (n = 21)

9

6

5

1

-

Week 16 (n = 18)

11

6

1

-

-

Week 22 (n = 17)

4

8

5

-

-

Week 32 (n = 19)

9

8

2

-

-
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Week 38 (n = 14)

4

8

1

1

-

Note: Likert scale scores ranged from 0 = no weakness, 1 = mild weakness in non-injected muscles, 2 = mild
weakness in injected muscles, 3 = moderate weakness in injected muscles and 4 = severe weakness in injected
muscles.

4.4. Discussion
Although tremor is not the most disabling symptom in PD, patients perceive tremor as an
important symptom that requires treatment.4 Benefits from recommended treatments for PD
tremor are often unsatisfactory and result in side effects of these medications.23 In addition,
for PD patients with tremor as their only troublesome symptom, treatment with current oral
medications becomes a therapeutic dilemma as these drugs may contribute to motor
fluctuations and dyskinesia later in life. Hence, levodopa sparing becomes an important
variable to consider in treatment of tremor. Previous studies have shown botulinum
neurotoxin type A (BoNT-A) injections as a possible focal treatment for tremor, although
finger and wrist extensor muscle weakness and dose-dependent limb weakness frequently
occurred.14,15,18,24,25 Brin MF et al and Pullman SL et al applied a fixed-dosing regimen and
subjectively determined injection sites which resulted in the occurrence of dose-dependent
hand weakness thereby reducing any functional efficacy of BoNT-A.14,15 Trosch RM and
Pullman SL demonstrated in an open label study that five of the ten PD patients moderately
improved in clinical tremor scores though accelerometry measures for rest tremor did not
significantly change.18 The limitations of these prior studies that reduced the effectiveness of
BoNT-A therapy were attributed to single injection studies, visually selecting muscles to
inject or using fixed-dosing parameters regardless of the patient’s tremor severity. As such,
BoNT-A for PD tremor is not widely adopted in clinical practice based on these past results.

The present study demonstrates that by individualizing BoNT-A injection parameters based
on the biomechanical pattern of tremor at the wrist, elbow and shoulder joints, targeted focal
therapy greatly improved efficacy without impairing arm function. As accelerometers placed
on the hand/fingers cannot distinguish and segment tremor originating from wrist, elbow, or
shoulder joints,26 this study simplified the complexity of tremor by utilizing sensor-based
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recordings in conjunction with custom-written software to characterize each patient’s tremor
profile.27 Kinematics allows independent and separate characterization of joint motion along
the arm for every patient, which is not possible with visual assessments. Furthermore,
injection patterns can be tailored to each patient’s kinematics (Figure 4) instead of depending
on visual methods or using a standard set of injections, as employed in prior studies.14

The significant, palliative effect of incobotulinumtoxinA on whole arm tremor severity was
clearly demonstrated both clinically and kinematically (Figure 5). Kinematically determined
BoNT-A parameters showed efficacious results by observing a significant decrease in
(UPDRS item 20) for all study time-points following the first treatment. Action tremor
(UPDRS item 21) severity demonstrated a trending decline in rating though this was not
significant (Figure 5a). Likewise, FTM tremor severity score displayed significant
improvement in rest, postural and action tremor at week six which continued to week 38.
Those seven participants who found tremor to be functionally bothersome at baseline
demonstrated significantly improved eating and function of daily tasks, a significant
enhancement in quality of life (Figure 5b). These functionally beneficial improvements in
fine and gross motor skills continued to occur following the peak effect of BoNT-A. Reduced
maximal grip strength during peak activity of BoNT-A (Figure 5f) was not perceived to be
functionally bothersome as participants rated such weakness as a 1 out of 4 on the Likert
scale, indicating mild weakness in injected muscles. Though maximal grip strength
decreased by 25% following the first treatment and 57% of participants (12/21) experienced
third finger extensor weakness, this was perceived as slight to mild weakness though these
effects were reported as not troublesome. This demonstrated that kinematically-based BoNTA injection patterns minimize the likelihood of adverse functional impairments.14 As
weakness in non-injected muscles (e.g. finger extensors) and in injected wrist muscle groups
did occasionally occur, a need for further refinement of injection techniques is required for
future studies, such as incorporating ultrasound-guided injections could be considered.16
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Dosages per muscle, in particular elbow and shoulder muscle groups (Table 3), were
substantially lower than previous studies involving treatment of PD, cerebellar and essential
tremor.15 As dosing was calculated based upon the quantified tremor amplitude, the best
medicated i.e. “ON” state was chosen. Thus, tremor treatment with BoNT-A was provided
concomitantly over and above the best treated oral medication state. An average of eight
muscles was injected, which was more than prior literature reported value.24,25 It is possible
that kinematic determination of joint dynamics of tremor would allow better optimization of
injections, thereby reducing muscle weakness.15

4.4.1. Study Limitations
Study limitations were non-blinded injections and having no treatment comparator and as this
was an open-label study, results are subject to bias. As outcomes in this longitudinal study
are both qualitative and quantitative, a persistent placebo response is unlikely. Since
weakness is obvious to perceive by both the clinician and the participant, long-term blinded
studies with BoNT-A are challenging to conduct. Validated clinical rating scales were used
as primary endpoints of this study, though a need for better functional assessment scales,
such as a patient global impression of change, could be incorporated for future studies.
Comparative studies investigating the use of surface electromyographic (EMG) alone versus
kinematics for tremor localization and assessment may also be useful to confirm this study’s
results. In addition, since tremor is variable, fluctuations in severity during each visit
introduced error. However, participants were assessed around the same time of day and in the
“ON” state. Visually-based versus kinematically-based treatments were not compared as the
prior studies have already shown the lack of reproducibility and tolerability using visually
guided, fixed schedule injections.11-15,17,18 Sample size is similar to other reported studies in
literature discussed.2,11-15,18,21,24,25,27

4.5. Conclusion
This study shows that individual, objective measurement of tremor at each joint in the upper
limb affected by tremor allows for proper characterization and treatment of PD patients.
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When achieved, such characterization can be used to guide the clinician’s muscle selection
for treatment of tremor. In PD tremor, individualized and optimized dosages of
incobotulinumtoxinA can be used successfully and without significant severe weakness over
a series of injections.
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5. General Discussion and Conclusion
The current thesis demonstrated the insight of measuring the biomechanics of limb tremor at
each joint in ET and tremor-dominant patients with PD. Wearable, multi-sensor kinematics
provided the ability to differentiate ET and PD kinematic tremor profiles and apply kinematic
analysis to personalize BoNT-A focal therapy by guiding muscle selection and dosing. These
findings revealed any changes in wrist or elbow tremor amplitude were related to shifts in
limb position either between paired rest tasks in PD or between paired postural tasks in ET.
In addition, detailed segmentation of joint tremor allowed individualization of BoNT-A
therapy and optimization of BoNT-A parameters over serial treatments thereby minimizing
the likelihood of side effects, mainly muscle weakness. This pilot study established an
innovative method that can easily be translated into the clinical setting as an objective
diagnostic aid, and when utilized by a clinician to monitor changes in symptoms to improve
focal therapy.

5.1. Technology for differentiating pathological tremor forms
The peak frequency of pathological tremor forms, such as ET and PD tremors, tends to
remain unchanged between different limb positions and under loaded conditions.1 It is
possible that tremors with similar frequencies may arise from similar central generators.2 Due
to the involuntary nature of tremor and its widespread appearance during various motor
activities, literature suggests that tremor may be a derivative of corticomotor pathways.2
Oscillations in the motor cortex have been shown to modulate descending corticospinal
pathways which could manifest in the muscle’s EMG and produce oscillatory movements.2
In addition, as motor deficits and pathological tremors go hand in hand, it is considered that
unlike physiological tremor, pathological tremors could be modulated peripherally.2 The
magnitude of pathological tremors, such as ET and PD tremors, are sensitive to somesthetic
inputs.1,3 It has been noted that ET and cerebellar tremors are more inclined to be influenced
by peripheral reflex modifications than PD tremor.2,3 Consistent with this evidence, it was
observed, from the results presented in this thesis, that limb positioning and weight-bearing
tasks modulate tremor amplitude in ET more than in PD. The findings discussed in Chapter 2
demonstrated that weakly correlated wrist or elbow tremor amplitude between posture tasks
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was distinctive to ET, as this was not observed in PD participants. In addition, when the
elbow is maximally flexed and the hand is positioned near the chest holding a weighted
object, there was a significant increase in elbow tremor amplitude in ET participants only. As
the pattern of agonist-antagonist muscle bursting has limited diagnostic value, these results
have demonstrated that observing correlations of joint tremor amplitude during various limb
positioning and weight-bearing paired tasks is an useful method to distinguish between ET
and PD tremor forms. However, solely observing tremor amplitude was not sufficient in
further advancing the knowledge of the pathogenesis of these tremors. Pairing EMG analysis,
kinematic tremor analysis and new recording techniques such as magnetoencephalography
may be useful to correlate the nature of central oscillatory activity with peripheral
manifestations.

5.2. Personalization of BoNT-A therapy using kinematics
The success in the use of BoNT-A as a focal therapy for upper limb tremor has been limited
due to the inaccuracies of visual assessments in determining muscles contributing to tremor
and the appropriate dosages administered to alleviate tremor amplitudes. Past studies have
used objective measures such as accelerometers and magnetometers to quantify overall joint
tremor, however further segmentation of joint tremor is necessary for muscle selection.
Kinematic technology has advanced the ability to distinguish tremulous movements at each
arm joint. The findings in this thesis demonstrated that when kinematic tremor analysis is in
the hands of a clinician, this simplified establishing which muscles to target and the
necessary BoNT-A dose to administer. A reduction in both tremor amplitudes and functional
disability caused by tremor was observed in PD and ET participants. In addition to
determining initial BoNT-A parameters, this study also demonstrated that kinematics can
play a major role in optimizing or modifying BoNT-A dosages for long-term, stable
management of tremor over serial BoNT-A treatments. Thus, the use of kinematics provided
a standardized method for both assessing and treating upper limb tremor in ET and PD
participants.
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5.3. Future directions
Effective management and development of new treatment strategies for disabling and
degenerative diseases remains a significant unmet need as relevant cures or neuroprotective
strategies are limited in the movement disorders field. The use of objective, wearable devices
in medicine has significantly advanced over the past decades and has been applied in all
facets of everyday life allowing accurate ratings/assessments and long-term monitoring of
clinical symptoms. As this thesis demonstrated that wearable technology can be used to
differentiate between PD and ET tremor forms and can be applied to improve localized
therapeutic regimens, it is of current interest to use kinematic technology to better classify
other pathological tremor types. Misdiagnosis rates in tremors are high due to the difficulty
to classify several forms of tremor using the current MDS classification system. Clinical
diagnosis cases with solely PD with rest tremor without convincing other signs of PD can be
misinterpreted as essential tremor with rest tremor, dystonic tremor, Holmes or thalamic
tremor or a few even rarer conditions.4 Many patients with primary tremor, such as
asymmetric rest and postural tremor, may not fit the current MDS criteria for other tremor
entities and are ultimately termed “undetermined tremors”.4 Thus, the use of kinematics has a
bright future in the hopes that a more comprehensive semiology and better separation of
different tremors can be achieved.
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Appendix B: Letter of Information

Letter of Information
Study Title: Use of kinematic assessment of hand tremor pre- and post- treatment with
botulinum toxin type A in essential tremor and Parkinson disease
Principal investigator: Dr. Mandar Jog, London Health Science Movement Disorders
Clinic, UWO

Introduction

We are inviting you to voluntarily participate in a research project designed to evaluate hand
tremor. Hand tremor is an unintentional, rhythmical, shaking of one or both hands. This
project aims to study tremor before and after injection of a medication called Xeomin® (a
form of botulinum toxin A), which can be used to manage tremor.

Study Funding

The study is funded by a research grant from Merz Pharma, which is the company that
produces the medication used in this study.
Nature of the research project and tasks involved

We are looking to investigate tremor in participants with tremor either because of Parkinson
disease or Essential tremor recruited from the Movement Disorders Clinic at London Health
Sciences Centre (LHSC). This study requires you to attend a total of 9 visits over the course
of 96 weeks. IF the previous 96-week (extended) study treatment has benefited you, you
have the option to continue in this study for an additional 8 more injection cycles for
another 2 years.
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You will not have to change taking your medications in any way for this study. Participation
in this study will not affect the routine management of your Parkinson disease or Essential
Tremor. Scheduling of your routine clinic visits will not change.

You will be required to bring your Parkinson disease medications with you to each visit so
that you may take them in accordance with your routine scheduled times.

You are eligible for the study based on the following: 1) a diagnosis of Parkinson disease
with tremor as the predominant symptom or Essential Tremor and 2) hand tremor severe
enough that it affects your quality of life and 3) you are a candidate for tremor treatment
using Xeomin, a formulation of botulinum toxin A as determined by your movement
disorders neurologist. 4) Experienced a beneficial reduction in tremor using Xeomin® and
would like to continue receiving injection treatments.

Pregnancy: If you are pregnant then you CANNOT BE IN THIS STUDY. Pregnancy
screening will take place before study admission by the physician, Dr. Jog. A researcher will
ask you about pregnancy at every study visit. Please notify the research team if you are
presently pregnant or if you are attempting to become pregnant or if you become pregnant at
any time during the course of the study. If this becomes the case, participation in this study
may be terminated.

Other Muscle/Nerve diseases: If you have a disease called Myasthenia Gravis or
Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig’s disease) then you CANNOT BE IN
THIS STUDY. Please notify the research team if you have these conditions.

Previous side effects to botulinum toxin: If you have had a previous allergic reaction or side
effect to botulinum toxin then you CANNOT BE IN THIS STUDY. Pease notify the research
team if you have had a previous reaction/side effects from injection of botulinum toxin.

The research visits will require you to come to Dr. Jog’s research facilities located at
University Hospital London, Ontario.
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At each visit you will be asked to complete the following tasks, which are described in detail
below:

Complete an assessment of your motor function
Complete an assessment of the severity of your tremor
Complete an assessment of how your tremor affects your quality of life
4)
IF injection parameters are not reducing tremor to an acceptable level, a project
member will perform a kinematic assessment of your tremor to modify injection sites, upon
approval by Dr. Jog

Kinematic Assessment of Tremor:
You will be asked to change into a hospital gown (top only you will not have to take off your
pants/skirt) so that the researchers may examine your full arm. You will have sensors placed
(using tape that is safe for your skin) onto your arm and hand in order to measure the tremor
(see picture below). In addition to the sensors that record the frequency (rate) and amplitude
(size) of your tremor movements, we will also use video cameras to record what your tremor
looks like.

You will be asked to do several tasks such as resting your arms in your lap, extending your
arms out in front of you, pouring water, etc. so that your tremor can be measured across a
variety of postures/activities. This will take approximately 20 minutes.
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Motor function:
During each visit, a researcher will complete the United Parkinson’s Disease Rating Scale
(UPDRS). This is the same assessment that your neurologist completes with you during your
routine clinic visit. It measures aspects of motor function such as: stiffness, tremor, walking,
activities of daily living, speech, etc. It is a non-invasive assessment and will take
approximately 10 minutes to complete. We will also measure the strength in your hand and
fingers at each session.

Tremor Severity:
During each visit a researcher will complete the Fahn, Tolosa, Marin Tremor Rating Scale. It
rates the severity of your tremor and during activities such as writing and asks you to rate the
severity of your tremor during different daily activities. It is a non-invasive assessment and
will take approximately 10-minutes to complete.

Tremor Quality of Life:
During each visit a researcher will complete a questionnaire called QUEST with you. Goal
attainment scale for tremor (GAST) will be completed by you and a care-giver, if applicable.
It asks you to rate how your tremor affects your quality of life. It is a non-invasive
assessment and will take approximately 10-15 minutes to complete.

Xeomin Injections: At each study visit, you will receive injections of Xeomin for the
treatment of your tremor symptoms. IF you choose to continue this study after
completion of the initial 13 visits, you can receive 8 more injection cycles at 3 months
apart for another 2 years. Dr. Jog will inject the muscles that are involved in your tremor
movements based on information from the kinematic assessment.

Injections are made using a small needle. The amount of Xeomin injected and the number of
different muscles injected varies with each individual and each muscle and is done at the
clinical discretion of Dr. Jog based on accepted clinical practice.

IF sufficient reduction in tremor is not at an acceptable level, Dr. Jog may make
modifications to the amount and site of injections. This decision will be based in part on your
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response to the previous injections and your perception of improvement in your tremor. This
will be done to try and achieve the best response in reduction of tremor with the medication.
Benefits, risks and inconveniences

You may not benefit directly from participation in this study. However, the results may
contribute to treatment of tremor. The cost of the medication will be covered during the
course of the study.

Some individuals may be uncomfortable with being video taped. However, the research
team is only recording your arms in an attempt to study your tremor.

Some individuals may be uncomfortable with having to change into a hospital gown.
However, a private change area will be provided.

Risks associated with Xeomin
As with any medication call your doctor or get medical help right away if you have any
side effects. Prior to being eligible for this study, your movement disorders neurologist
has made the decision to start you on this medication as a part of a plan to manage your
tremor. As with starting any new medication, questions regarding taking this medicine
or side effects should be addressed with either your physician or your pharmacist prior
to starting this medication.

Xeomin may cause serious side effects that can be life threatening.
Problems with swallowing, speaking, or breathing. These problems can happen hours to
weeks after an injection of Xeomin if the muscles that you use to breathe and swallow
become weak after the injection.
People with certain breathing problems may need to use muscles in their neck to help them
breathe. These patients may be at greater risk for serious breathing problems with Xeomin.
Swallowing problems may last for several months. People who cannot swallow well may
need a feeding tube to receive food and water. If swallowing problems are severe, food or
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liquids may go into your lungs. People who already have swallowing or breathing
problems before receiving Xeomin have the highest risk of getting these problems.

Spread of toxin effects. In some cases, the effect of botulinum toxin may affect areas of the
body away from the injection site and cause symptoms of a serious condition called botulism.
The symptoms of botulism include:
loss of strength and muscle weakness all over the body
double vision
blurred vision and drooping eyelids
hoarseness or change or loss of voice
trouble saying words clearly
loss of bladder control
trouble breathing
trouble swallowing

Xeomin may cause other serious side effects including allergic reactions. Symptoms of
an allergic reaction to Xeomin may include: itching, rash, redness, swelling, wheezing,
asthma symptoms, or dizziness or feeling faint. Tell your doctor or get medical help right
away if you get wheezing or asthma symptoms, or if you get dizzy or faint.

The most common side effects of Xeomin include:
dry mouth (up to 5%)
discomfort or pain at the injection site (up to 5%)
tiredness (less than 1%)
headache (less than 1%)
neck pain (up to 5%)
muscle weakness of injected muscles (less than 1% at a distant site)
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eye problems, including: double vision, blurred vision, drooping eyelids, swelling of your
eyelids, and dry eyes. Reduced blinking can also occur. Tell your doctor or get medical help
right away if you have eye pain or irritation following treatment. (up to 5%)

While the above side effects can occur side effects are usually linked to site of injection
and therefore vary widely among people depending on where they are injected and for
what reason. For injections in the hand/arm the most common side effect is weakness in the
hand or arm muscles. Tell your doctor if you have any side effect that bothers you or that
does not go away.

Data collection and use of information

Participation is voluntary. Information and data obtained in the study will not be labeled
with any of your personal information (name, initials, date of birth, medical record number,
etc.).

The data from the study will be kept electronically and securely using the LHSC computer
network. At all times, the data will be in the possession of one of the investigators of this
study and will not be stored off-site.

For the purposes of contacting you to arrange the data collection sessions and linking your
data from the multiple visits, we will keep a master list of all participants. This list will
contain your first name, telephone number, address, the dates you completed your sessions,
and a number that we will assign to you that will also appear on your data recordings. At the
conclusion of this study, this master list will be destroyed.

Your signed consent, which will have your name on it, will not be stored with the data
collected from the study and will not be connected to the data collected. The master list with
your contact information on it will also be stored separately from the data collected to avoid
linking your personal information to your data recordings. Consent forms and the master list
will be stored in a secure location in the Movement Disorders Laboratory of Dr. Jog at
University Hospital.
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Any use of this information for publication in scientific journals or presentation at
professional conferences, will not contain any of your personal information that could be
linked back to you or to your health information.

You will receive a copy of this information letter for your records.
Withdrawal from the study by the investigator

The investigator may decide to take you off the study if he feels your continued participation
would impair your wellbeing.

Monetary compensation

You will not be paid for participation in this study. Parking will however be compensated at
$20.00 for each visit required by the study.
Confidentiality

In order to preserve your confidentiality, only the investigators in this study will have access
to your research information. No personal information will be collected or retained with
your data. AT NO TIME, will your name be used in scientific presentations or publications.
The recorded data will remain secure, accessible only to research personnel.

Representatives of the University of Western Ontario Health Sciences Research Ethics Board
may contact you or may require access to your study related records to monitor the conduct
of the research.

Voluntary participation
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Participation in this study is voluntary. You may refuse to participate, refuse to answer any
questions or withdraw from the study at any time with no effect on your future care.

You will be able to withdraw from the study at any point in time. However, to protect the
integrity of the study the data collected up to the point of your withdrawal will remain a part
of the study. You will not have the option of withdrawing your data once it has been
collected even if you choose to withdraw from the study.
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PATIENT CONSENT FORM
STUDY TITLE
Use of kinematic assessment of hand tremor pre- and post-treatment with botulinum toxin type A in
essential tremor and Parkinson disease

I have read the Letter of Information, have had the nature of the study explained to me and I agree to
participate. All questions have been answered to my satisfaction.

Signature of Research subject

Printed Name

Date

Signature of Investigator

Printed Name

Date

Signature of Person Obtaining Consent

Printed Name

Date

109

Appendix C: Fahn-Tolosa-Marin Rating Scale
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Appendix D: Unified Parkinson’s Disease Rating Scale
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Appendix E: Quality of Life in Essential Tremor Questionnaire

116

117

Appendix F: Manual Muscle Testing
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